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ABSTRACT
CEREBRO-VASCULAR DISRUPTION MEDIATED INITIATION AND
PROPAGATION OF TRAUMATIC BRAIN INJURY IN A FLUID PERCUSSION
INJURY MODEL
by
Xiaotang Ma
Traumatic brain injury (TBI) is a major health problem for over 3.17 million people in
the US. There is no FDA-approved drug for the treatment because the injury mechanisms
have not been clearly identified. The knowledge gap is addressed here by the lateral fluid
percussion injury (FPI) rat model, through the understanding of layer-structured
mechanisms from physical vascular rupture to acute necrosis, as well as biochemical
changes in perivascular space as secondary events.
Firstly, the cerebrovascular hemorrhage and related infarct volume are
investigated as the primary events in moderate FPI, which is found to be increased with
injury severity in FPI. The extent of coagulation is validated by the bio-distribution of
fluorescent tracer in the cerebrospinal fluid (CSF) pathway after the injury. Biodistribution of the tracer is specifically diminished at the site of coagulation, which
blocks the CSF movement in subarachnoid and interstitial spaces. The pattern of
coagulation is associated with the CSF blockage and correlates to necrotic cell death in
and around the impact site. Different biomarkers for immune cells, neuronal death and
tight junction proteins show that physical disruption of vasculature plays an important
role for the acute induction of neuroinflammation and neurodegeneration in blunt TBI.
Additionally, free radicals generation is found to be significantly increased in the
injured hemisphere immediately post FPI and decreases over time. Upregulation of
radical-generating enzymes, NADPH oxidase 1 as well as inducible nitric oxide synthase,

initiates biochemical damage of the injured brain. As a result, the signatures of
oxidative/nitrosative damage markers 4-HNE and 3-NT are observed in the blood brain
barrier (BBB) post-TBI, with temporal changes in the injury site. Oxidative/nitrosative
damage and immune cells infiltration correlate with gliosis at 4 hours and 7 days post
moderate FPI. Examination of apoptosis, tau phosphorylation, and neuronal survivability
at day 7 post FPI further validate neurodegeneration. Thus, it is confirmed that the acute
and long-term neuroinflammation and neurodegeneration are correlated with cerebral
vascular disruption.
Finally, novel regenerative medicines are explored for in-situ repair with
angiogenesis and neuroprotection mechanisms in the injured brain post-TBI. An
injectable self-assembling peptide-based hydrogel (SAPH) appended with vascular
endothelial growth factor (VEGF) mimic is used to create a regenerative
microenvironment for neovascularization at the injury site. VEGF is an angiogenic and
neuroprotective growth factor that is involved in the process of brain repair.
Supramolecular assembly allows for thixotropy; the injectable drug delivery system
provides sustained in vivo efficacy. Application of the angiogenic SAPH directly in the
injury site promotes disrupted vasculature repair in and around the hydrogel implant at
day 7 post-TBI. Upregulation of VEGF-receptor 2 is observed, demonstrating an
angiogenic response in the presence of angiogenic SAPH. Moreover, vascular markers
von-Willebrand factor (vWF) and α-smooth muscle actin (α-SMA) show a concomitant
increase with blood vessels in response to the angiogenic SAPH. The neuronal rescue
examination by NeuN and myelin basic protein shows that the SAPH has the potential to
provide neuroprotective benefits in the long-term recovery.
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CHAPTER 1
INTRODUCTION
1.1 Traumatic Brain Injury
Traumatic brain injury (TBI) is a major cause of death and disability in the world,
particularly caused by an external insult in the battlefield or in civilian life [1]. There
are about 2.2 million people who suffer TBI each year in the US, which accounts for
more than 3.2-5.3 million people living with a life-long disability [2]. Incidence of
TBI is still rising with 2.8 million TBI-related emergency hospital visits and deaths
in 2013 in the US. These TBI patients consist of about 54% children and 79% seniors
that resulted from falls [3]. The incidence of motor vehicle accidents, athletic sports
head injury, and blast-wave diffuse injury are also major causes of TBI [4]. Many of
these brain injuries when left untreated or without properly management, lead to
development of cognitive/behavioral impairment [5, 6], PTSD [7-9], chronic
encephalopathy [10-12], epileptic seizure [13, 14], and neurodegenerative
Alzheimer’s disease [15-17].
TBI is a complex disease process causes structural damage and functional
impairment due to primary and secondary injury mechanisms. The primary injury is
immediately caused by a mechanical pulse on the brain tissue at the time of exposure;
this process includes surface contusion, damage to blood vessels, laceration, and
axonal shearing. Secondary injury happens minutes to months after the primary
injury, resulting from cascades of metabolic, cellular and molecular events that lead
to brain cell death, tissue damage and atrophy [18]. Common features are apnea and
hypoxia, which leads to ischemia of the brain. Many biochemical mechanisms
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underlying TBI pathophysiology have been confirmed, such as oxidative stress,
glutamate excitotoxicity, inflammation, apoptosis and necrosis in animal model
studies [19]. Cell death happens within minutes to months post TBI, and necrotic
and apoptotic cell death occurs specifically in contused areas and the boundaries,
leading to cognitive deficits and neurodegeneration [20].
Over the past decades, despite numbers of phase III clinical trials of TBI
pathophysiology modulating candidates, no treatment has been shown to be
efficacious [21, 22]. The reasons of failures were complicated, and the underlying
mechanism of TBI is not well understood yet, as the patients are always present with
complicated lesions of different severity and regional distribution. There are two
main types of TBI insults; focal and diffuse injuries. Focal injuries are localized
damages at the site of the impact, characterized by contusions and lacerations,
leading to local hematoma. Diffuse injuries are with brain swelling, diffuse axonal
injury (DAI) and ischemic brain injury both at the impact site and remote sites [23].
But some brain injuries are mixed injuries with focal and diffuse injury patterns.

1.2 Experimental Methodology in Traumatic Brain Injury
Animal models have been used to recapitulate salient features of TBI pathophysiology.
Although there is no specific animal model that can accurately mimic human brain
injury [24]. Notwithstanding, these animal models of TBI offer a viable alternative to
examine the biomechanical, cellular and molecular mechanisms of TBI-associated
neuropathological progression and the time-dependently effects. Table 1.1 shows
current animal models of TBI, the types of injury, the clinical relevance, and the
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strengths or the weaknesses of each TBI model within the category of focal, diffuse,
and mixed mechanisms of injury.

Table 1.1 Animal models of experimental TBI.
Model

FluidPercussion
Midline
Lateral

Injury

Mixed
Mixed

Controlled
Cortical
Impact
Open-skull

Mainly
focal

Closed-skull

Direct
brain
deformation.
Cerebral
concussion
Example:
Sports related
TBI: Boxing,
Football
Direct
brain
deformation.
Cerebral
concussion
with
subarachnoid
hemorrhage.
Example:
Sports related
TBI: Boxing,
Football

Weight Drop

Mainly

Feeney

focal

Shohami

Mainly

Marmarou

focal
Mainly
diffuse

Blast Wave
Model
Shock/blast
tube

Clinical
Relevance

Diffuse

Hemorrhage
and
diffuse
axonal injury.
Example:
Falling down,
Motor vehicle
accidents

Blast
Wave
induced TBI
(Battle field)

Strength

Severity of injury
can be adjusted;
inflicted injury is
highly reproducible
within
one
laboratory

Weakness
Requires craniotomy that may
compensate for ICP increases;
no
immediate
post-injury
neuroscoring;
possible inflicted injury is
variable between different
laboratories;
high mortality rate due to
apnea

Severity of injury
can be adjusted,
inflicted injury is
highly reproducible

Requires craniotomy;
no
immediate
post-injury
neuroscoring

Mechanism
is
similar to human
TBI, severity of
injury
can
be
adjusted;
well characterized
neuroscoring;
immediately after
injury
allows
randomization;
inexpensive

High mortality rate due to
apnea and skull fractures; not
highly
reproducible;
high
variability in injury severity

Similar to soldiers
in battle field.

Not so precise
human TBI

mimicking

Source: [25]

To evaluate the efficacy of therapeutic treatments, the assessment of injury
severity post TBI has played a critical role. In clinical settings, Glasgow Coma Scale
(GCS) [26, 27] or improved/extended GCS (GCSE) [27] is used for the severity of
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TBI diagnosis and prognosis. The GCS is based on a 15-point neurological scale
according to eye, verbal and motor movements. The clinical guidelines incorporating
duration of loss of unconsciousness and structural imaging with GCS, classify human
TBI into mild, moderate and severe level. However, there is no established guideline
or standard to assess injury severity in experimental TBI, making it challenging to
translate animal models to clinical studies. For decades researchers have discussed
different parameters to grade injury severity according to each model: the mechanical
parameters such as the peak pressure or duration; neurological changes including
apnea, righting reflex time and pinna reflex; physiological changes with weight loss
or intracranial pressure increment; behavioral changes in neurological severity score
(NSS) or motor function tests; histological changes indicated by infarct volume and
neuronal loss. But untill now, there is no consensus because of the different
mechanisms from these animal models.
Each experimental model of TBI has its own mechanical properties for the
physical insult. To summarize, the principal causes of focal brain injury producing
localized tissue damage resulted from a blow to the head, car accidents or violent
assaults, while diffuse injury is caused by acceleration or deceleration impact
including the unrestricted head movement in motor vehicle accidents or blast-wave
propagation [28]. The mixed injury model represents the types of head injury
resulting from falls or athletic sports injury. The rat model of fluid percussion injury
(FPI) typifies the mixed injury, the open-skull controlled cortical impact (CCI) model
approximates focal injury, and shock-wave blast model represents diffuse injury.
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1.3 Fluid Percussion Injury
Mixed Injury Model- Lateral fluid percussion injury model (FPI): FPI is one of the
best characterized and most often used animal models of TBI. The injury in FPI is
induced by a pendulum striking the piston at the end of a tube filled with fluid,
shown in Figure 1.1. The fluid pressure impulse then hits the exposed dura directly
through the Luer-Lock that has been implanted surgically by craniotomy [29].
Briefly, a Luer-Lock is positioned above a 3.0 mm diameter opened skull circular
window, which is connected to FPI device fluid impulse outlet and fluid pressure
detector. In this way, the fluid pressure delivered on the exposed dura is accurately
measured by the detector at the time of injury. The location of the craniotomy defines
the types of injury in FPI models. Thus, when craniotomy is performed at the center
of the sagittal suture, it is known as Midline FPI [30]. But the mortality of MFPI is
higher than other models, which is believed to be due to brainstem-compromised
apnea [31]. In Lateral FPI, craniotomy is performed at 3.5 mm lateral to midline [32],
and for parasagittal FPI, the Luer-Lock is implanted less than 3.5 mm lateral to
midline [33, 34]. Brain tissue deformation, displacement, and severity of the injury in
these types of FPI are resulted from fluid pressure pulse [32]. The pathophysiological
changes in FPI are correlated with the pressure transients, in which upper mild,
moderate or severe type of pressure impulse causes focal and diffuse injury, while
the lower threshold of mild pressure impulse produces diffuse injury [35].
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Figure 1.1 Fluid percussion injury model. The fluid pulse impacts at the exposed
dura by craniotomy. Source: [25].
The application of FPI model is used for replicating the human TBI without
skull fracture that generates edema, hemorrhage and gray matter damage [29]. The
primary

type

of

injury

in

fluid

pressure

impulse

includes

contusion,

shearing/stretching of tissue, subdural hematoma, and hemorrhage as seen in
concussive sports injury [36]. Such primary injury is followed by secondary
mechanisms of molecular, biochemical, and cellular changes arising from focal and
diffuse injury. The vascular disruption like hemorrhage and on-site necrotic cell
death are likely an outcome of primary injury, while activation of inflammatory glial
cells and neuronal cell death could be resulted predominantly from secondary
mechanisms of injury. The Lateral Fluid Percussion Injury (LFPI) model has the
advantage of comparing the extent of damage in ipsilateral (injured side) and
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contralateral (non-injured side) of the brain hemisphere. LFPI produces focal cortical
contusion and diffuse subcortical neuronal injury in the ipsilateral side of the brain
[37], which is also believed to be not extended in contralateral hemisphere. A postinjury lesion scar is generated around glial cells at the impact site, which appears to
result from continuous chronic cell death [38]. This progressive neurodegeneration
that begins from seconds up to a year post-injury at the ipsilateral side of brain region
appears to occur predominantly at the cortex, hippocampus, thalamus, striatum and
amygdala [39].
Such differential regional neurodegeneration in LFPI is able to reproduce
neurobehavioral impairments that are observed in TBI patients, such as reflex
suppression, vestibulomotor function and cognitive function [23, 40]. Such
impairments are believed to continue for years after severe LFPI [41]. The reliability
and reproducibility of FPI-induced neurodegeneration, neurological impairments, and
mortality rate are dependent on the location of craniotomy because a small shift from
the midline FPI (MFPI) can cause significant changes in brain infarct volume and
neurological outcomes. The evolution of recent computer-controlled LFPI device that
can monitor the fluid-percussion waveforms with adjustable rise times, peak
pressures, and durations is an advanced reliable improvement to the model [42].
Injury Severity in FPI model: Perhaps the definition of mild, moderate and
severe injury is the best established in animal model of FPI. The strength of the
injury classification lies in the combination of mortality rate, the pressure exposure
range, the righting reflexes, and reliable reproducibility of the injury model. For
example, Alder et al. (2011) performed mild to moderate injury in a mouse model of
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LFPI on the basis of mortality rate, pressure range, and righting reflexes [36]. Injury
pressures are delivered in the range of 0.9 - 2.1 atmosphere (atm) pressure that
produces mild injury with 0 - 5% mortality rate and a righting reflex time of 2 - 4
min, or moderate injury with a mortality rate of 10 - 20 % and a righting reflex time
of 6 - 10 min.
Kabadi et al. (2010) described mild, moderate and severe injury at 1.8–2.2 atm,
2.4–2.8 atm and pressures greater than 2.8 atm, respectively in standard lateral FPI
model (Amscien Instruments) [43]. They also established these classifications in a
new developed rat model of microprocessor-controlled, pneumatically driven
instrument, micro-FP device. With micro-FPI, pressures of 2.2–2.4 atm, 2.6–2.8 atm
and > 3.0 atm correspond to mild, moderate and severe magnitudes of injury,
respectively. They observed that mortality rates were 0% at 2.4 atm, 12% at 2.6 atm,
20% at 2.8 atm, 33% at 3.0 atm and > 65% above 3.2 atm. The cognitive
performance, lesion volume and neuronal loss were significantly different between
mild and moderate level. Similarly, Prins et al. (1996) classified the types of injuries
in a rat model of FPI through a comparative study on mortality rate, morphology,
intracranial pressure and mean arterial blood pressure [44]. They investigated mild
pressure range from 1.35-1.45 atm, moderate injury pressure range from 2.65–2.75
atm, and severe injury pressure range from 3.65–3.75 atm. The mortality rate
corresponding to mild, moderate, severe injury pressure range was respectively 27%,
36%, 100% for postnatal 17 days, and 0%, 20%, 55% mortality for adult rats [44].
They reported that the duration of apnea for adult rat was 10.4 secs; 20.3 secs; 24.9
secs and duration of unconsciousness was 97.8 secs; 183.0 secs; 291.2 secs for mild,
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moderate, severe, respectively. The increment of intracranial pressure and mean
arterial blood pressure appeared to contribute the mortality rate in the corresponding
mild, moderate, severe injuries. Moreover, weight loss post injury is also correlated
with injury severity. Mild, moderate and severe injury was found to result in 0-10%,
15-20%, 25-30% weight loss, respectively [45]. Meanwhile, the injury severity range
was summarized after a literature research from FPI studies on mild, moderate and
severe level, separately. After incorporating the data from the literature and the work
established in our laboratory, it was defined here that mild FPI range at 0.9-1.5 atm
[46-48], moderate FPI at 1.6-2.5 atm [49-51] and severe injury above 2.5 atm [52-54].
The suppression time of reflexes such as pinna, cornea, and righting has been
established as a standard indicator of neurological evaluation in animal model
immediately after FPI. The pinna reflex is defined as a head shake or twitching of ear
when touching the inside of the pinna with a cotton-tip applicator. The corneal relax
is when there is a blink response after touching the cornea gently with a salinemoistened wisp of cotton. The righting reflexed is examined by recording the time
for the animal to roll over on their feet when they are placed on their back, for three
times [55]. The non-invasive righting reflex appears to correlate with injury severity,
thus it is used commonly as an indicator of injury severity [40, 56]. Apart from
righting, apnea, and pinna reflexes, the types of injury severity are also assessed by
physiological functions such as arterial blood gases, vital signs, intracranial pressure,
and electrophysiology.
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1.4 Specific Aims and Significance
In this study, I have examined the sequence of injury events of injury for a moderate
LFPI pressure pulse exposure in experimental TBI. Tissue deformation at the site of
impact includes rupturing the subarachnoid and pial vessels that leads to intracranial
hemorrhage of the ventricle area on the impact side. The subsequent event of
hemorrhage is likely to produce subarachnoid coagulation preventing effective
cerebrospinal fluid (CSF) clearance and thrombotic vessel occlusion. Such
hemorrhage and coagulative thrombosis resulting from primary focal contusive
injury causes necrotic cell death that is different from the secondary mechanisms of
injury/cell death as depicted in the two arms of schematic pathways (Figure 1.2).
The critical role of coagulation after cerebrovascular damage in trauma patients after
TBI has become a reality that a majority of TBI patients are treated with novel oral
anticoagulant therapy [57]. The primary injury leads to the propagation of secondary
mechanisms of injury. It involves the alterations of molecular, biochemical, and
cellular components that are mostly regulated by a sequence of signaling pathways.
For example, there is immediate induction of oxidative stress and infiltration of
immune cells at the deformed and vascular rupture area. In TBI, myeloid cells like
microglia and astrocytes are anticipated to active in response of ongoing immune cell
infiltration (right arm) and changes in brain microenvironment (left arm) as depicted
in the pathways (Figure 1.2). These cascades of inflammatory processes like the
oxidative stress, neuroimflammation, and apoptotic cell death comprise the
secondary mechanisms of brain injury and neurodegeneration.
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Figure 1.2 Schematic of moderate lateral fluid percussion injury. Source: [25].
The overarching objective in this dissertation is to uncover the mechanisms of
TBI in layer structured neurovascular units in preclinical measures as reliable
predictors for clinical assessments, as well as development of regenerative treatments
targeting the cerebrovascular repair. The objective was achieved by examining the
hypothesis that cerebrovascular damage post FPI leads to acute necrosis, then
develops to neuroinflammation and neurodegeneration, and angiogenic modulation
may have the potential for neuroprotection. Success of this goal rests on three
Specific Aims:
Aim 1: To establish that physical disruption of cerebro-vasculature post TBI
leads to coagulation, necrotic cell death and onsite inflammation. First, it was
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established that hemorrhage at the side of injury causes necrotic cell death around the
site of injury. Hemorrhagic infarct area of the brain was analyzed by histology
staining, and then followed by imaging of fluorescent tracer contrast (high 2000 kDa
and low 3 kDa MW) bio-distribution to determine the thrombotic blockage at the
cerebrospinal fluid (CSF) clearance routes following intracisterna magna or
intravenous injection. Second, staining of coagulation factor XII, thrombin and blood
platelets confirmed thrombotic sites, and histological evaluation identified necrosis in
and around thrombotic site. Third, acute infiltration of immune cells around the
injury sites validated the onsite inflammation resulted from acute vascular damage or
subarachnoid hemorrhage. The extent of immune cell infiltration in specific brain
area, injured side or non-injured side was correlated with the hemorrhagic brain
infarct volume.
Aim 2: To examine the prolonged secondary events after cerebral disruption,
including oxidative/nitrosative damage in blood brain barrier (BBB), as well as
gliosis in response of acute immune cells infiltration. First, the generation of free
radicals at hemorrhagic site immediately post-injury was examined, as well as the
activation of the free radical generation enzymes and oxidative/nitrosative damage
markers. Second, in response of acute immune cells infiltration, microglia and
astrocytes activation was assessed in short and long-term post injury, particularly in
the injured brain side compared with non-injured side. Third, a delayed wound
healing is expected to induce apoptotic cell death correlated with tau
hyperphosphorylation and neuronal loss for neurodegeneration.
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Aim 3: To evaluate the efficacy of regenerative treatment targeting
angiogenesis and neuroprotection by injectable self-assembling peptide hydrogels.
Cerebrovascular disruption slows down wound healing, while thrombosis and
neuroinflammation are expected to cause prolonged neuronal loss. Injection of selfassembling angiogenic/neurogenic at the site of injury can promote in situ repair by
angiogenesis and neuroprotection longitudinally.
A better understanding of the injury mechanisms is expected to contribute
successful regenerative therapy for millions of trauma patients. Such effective
neuroprotective therapy is much needed for alarming incidence of 69 million
individuals worldwide who sustain TBI each year as per recent epidemiological
reports [4].
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CHAPTER 2
CEREBRAL VASCULAR RUPTURE IN THE MODERATE FLUID
PERCUSSION MODEL
2.1 Introduction
Traumatic brain injury TBI is clinically classified as mild TBI [58-60], moderate TBI
[61], severe TBI [62, 63], and vegetative state TBI [64] according to the 15-point
Glascow Coma Scale in humans. TBI leads to a high risk for neurological diseases
including post-traumatic stress disorder (PTSD) [65], chronic traumatic encephalopathy
(CTE) [66, 67], and Alzheimer’s disease (AD) [10, 15-17]. Most frequently observed
concussive TBI (88%) involves the development of brain pathology induced by traumatic
mechanical forces [68], resulting in temporary neurological dysfunction that is not
associated with brain structural changes [69]. About 25-42% of concussive brain injury
arising from contact sports [70-72], and vehicular accidents [73, 74] are alarmingly not
reported. Therefore, the benefit in understanding the injury mechanisms and possible
remedial approach will have significant impact for TBI patients.
Extensive research has been conducted to identify potential therapeutic targets
for TBI, but none have translated into successful clinical treatments. One major
consequence of TBI that has not been extensively investigated is cerebral vasculature
dysfunction. The disruption of vasculature causes the primary injury in the form of
blood-brain barrier (BBB) damage, hemorrhage, and coagulation, which can trigger the
progression of the inflammatory neuropathogenesis [75, 76]. Hemorrhage occurs in 46%
of all TBIs and is increasingly prevalent in moderate and severe injuries [77, 78]. The
effects of hemorrhage will result in increased intracranial hypertension, compression of
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brain structures, neuroinflammation, and even cognitive impairments in long-term [79,
80]. Hemorrhagic bleeding and subsequent coagulative thrombosis appears to be the
most challenging management for TBI patients in critical emergency care [81-83].
Thrombosis in cerebral microcirculation is known to cause ischemia, reduction in
blood flow, and accumulation of neurotoxic ferritin/hemosiderin [84-86]. In fact, a
predicator of worse outcome in TBI is believed to be a reduction of pericontusional
blood flow arising from thrombotic coagulation [87, 88]. In previous clinical studies,
anticoagulation treatments were attempted on TBI patients with moderate to severe
trauma, the results showed a marginal reduction of hypercoagulation when there was
no significant difference in mortality or outcomes [89-91]. These clinical observations
strongly indicate the importance of hemorrhage and thrombosis in managing the care
of TBI patients in the emergency room. In agreement with these clinical observations,
Stein et. al. (2002, 2009) reported that human cerebral contusions, lateral fluidpercussion injury (LFPI) in rats, and rotational acceleration head injury in pigs, all led
to a universal intracranial thrombin accumulation [92], and that therapeutic use of
erythrocyte-bound tissue plasminogen activator was effective in improving thrombin
associated brain injury [93]. Yet, the mechanisms of coagulation and secondary
propagated neuroinflammation and neurodegeneration in TBI remain elusive.
It is well established that neuropathology and clinical features of blunt head
injury can be reproduced in an animal model of lateral/midline fluid percussion injury
(LFPI/MFPI) [23, 25, 94, 95]. The insult is caused by a pendulum striking the fluid
reservoir to generate a pressure pulse to the exposed dura at a 3 mm window, resulting
in intracranial hemorrhage, contusion, neuronal injury and all pathophysiological
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hallmarks of human brain injuries without skull fracture [94, 96]. Here, this aim is
focused on understanding the sequential mechanisms of moderate brain injury in LFPI
model for possibly aligning the injury pathology and therapeutic approach in human
TBI. The novelty of the present work includes the layer-structured understanding of the
underlying mechanisms at different timeframes post-TBI: 1) cerebral vascular
disruption to hemorrhage mediated coagulation as the cause of primary injury, 2)
instant CSF pathway blockage, necrotic cell death and activation of immune cells as
the short-term secondary injury; 3) prolonged blockage of the CSF pathway correlating
to sustained coagulation generation. The uniqueness of these findings will pave the
path for understanding the mechanisms and developing a therapeutic treatment of TBI.

2.2 Methods and Materials
2.2.1 Reagents
All primary antibodies were purchased from Abcam (Cambridge, MA). Secondary
Alexa Fluor conjugated antibodies were purchased from Invitrogen (Carlsbad, CA).
Table 2.1 summarizes the details of the antibodies, including source, catalog numbers,
and

dilutions

factors

that

were

used

for

immunofluorescence

or

immunohistochemistry staining and western blot analyses. Dextran-conjugated
Fluorescein, 2,000,000 MW (FITC-d2000) was purchased from Thermo Fisher
(Waltham, MA).
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Table 2.1 Antibody Source, Catalogue Numbers, and Dilution Factors for
Immunohistochemical Staining and Western Blot Analysis

2.2.2 Experimental Animals
Adult male Sprague–Dawley rats (250-300 g; 8–10 weeks old) were purchased from
Charles River Laboratory (Wilmington, MA), and maintained in sterile cages under
pathogen-free conditions. All procedures followed the National Institutes of Health
guidelines for the ethical care of laboratory animals, and the Institutional Animal
Care and Use Committee (IACUC) at the animal facility of Rutgers-Newark
University. Rats were randomly selected and treated with different conditions as
follows: 1) Determination of optimal working pressure by brain infarct volume
variations in FPI (n=24): 4 rats per pressure (sham, 0.5 atm, 1.0 atm, 1.6 atm, 2.0 atm,
2.6 atm), and sacrificed the rats immediately after injury, without any transcardial
perfusion of paraformaldehyde (PFA) or PBS wash. Following the injury-severity
dependent study, 1.8-2.0 atm was used as the working pressure, to generate a
moderate injury with visible hemorrhage and infarct volume, but with a low mortality
rate of 7.5%. The recorded apnea time was 15-20 s, and the righting reflex time was
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8-10 mins. 2) Tracer bio-distribution under different pressure of FPI (n=20), 4 rats
per pressure (sham, 0.5 atm, 1.0 atm, 2.0 atm) at 4 hrs, and 4 rats for tracer
distribution in moderate FPI (2.0 atm) at 7 days post injury to check if there was any
repair mechanism. 3) Histological and biochemical changes in moderate FPI at 4 hrs
(n=12), 6 rats per sham control and FPI groups.
2.2.3 Fluid Percussion Injury
The fluid percussion injury (FPI) model (Amscien Instruments) is the most
commonly used animal model of traumatic brain injury. Briefly, the rats were
anesthetized with a mixture of ketamine and xylazine (10:1 (100 mg/10 mg/kg),
0.1 mL/100 g) and placed in a stereotaxic frame. Craniotomy was performed by
drilling a 3mm hole on the left parietal skull, 2.5 mm lateral from the sagittal suture
and 3.0 mm caudal from the coronal suture, with the dura intact. A Luer-lock hub
was glued on the skull over the exposed dura with cyanoacrylate gel, and secured by
application of methyl-methacrylate (Henry Schein, Melville, NY, USA). One day
after surgery, animals were anesthetized by isoflurane to receive either sham or
lateral FPI. Different injury severity levels were used in the preliminary studies
according to our previous publication [25]. Sham animals were anesthetized and
attached to the device without the injury. After removing the injury hub, the rats’
heads were sutured and the rats were returned to their cages.

2.2.4 Intracisterna CSF Tracer Infusion
Fluorescent FITC tracer (Dextran, Fluorescein, 2,000,000 MW, (Thermo Scientific,
Rockford, IL) reconstituted in artificial CSF (5 mg/ml) was infused into anesthetized
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rats via intracisterna magna [97], 2 hours before sacrifice. Anesthetized rats were
fixed in a stereotaxic frame and 10 microliters of CSF tracer was infused by a 30gauge needle at a rate of 1 µl/min for 10 mins with a syringe pump (Harvard
Apparatus). Small molecule tracer (Texas red, Thermo Scientific) was injected
through tail vein at the same time. To visualize the movement of tracer in the CSF
flow and into the brain parenchyma, animals were transcardially perfused with 4%
paraformaldehyde after 4 hrs of intracisterna infusion.
2.2.5 Anti-coagulant Treatment
Five rats were treated with tissue plasminogen activator (tPA, Sigma Aldrich) after
24 hrs post moderate FPI. Single dose of 5 µL dose (1mg/ml) was injected
intracranially through the impact site. Then the rats were sacrificed at day 3 post FPI
after FITC tracer injection through cisterna magna.
2.2.6 Tissue Processing
Animals were sacrificed at 4 hrs and 7 days at post-injury to harvest the brain tissue
for analysis. Blood samples were collected from the bleeding out of the Luer-lock
hub at the injury site for FPI rats, and from the carotid artery for sham controls.
Anticoagulant-treated tubes with sodium citrate were used for collection of blood
samples (10 μl sodium citrate/100 μl blood sample), and centrifuged at 2100 x g for
10 mins to get blood plasma. Brain tissues were immersed in 4% paraformaldehyde
overnight, followed by cryoprotection in 30% sucrose in PBS. Brain tissues were
snap frozen in Tissue-Tek OCT compound (Thermo Scientific, Rockford, IL) and
coronal sliced by Leica CM3050 cryostat into 20μm thick sections.
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2.2.7 Histological Staining
Cresyl Violet staining. The brain sections were stained in 0.1% cresyl violet solution
for 10 mins and then rinsed quickly in distilled water. Then the slides were immersed
in 95% ethyl alcohol for 10 mins, and dehydrated in 100% alcohol for 5 mins and
then cleared in xylene for 5 mins. H & E staining. The brain sections were stained in
hematoxylin for 15 mins, washed in running tap water for 15 mins, placed in distilled
water for 30 s, then counterstained in Eosin for 30 s. Afterwards the sections were
dehydrated with 95% EtOH and100% EtOH for 4 mins. They were then cleared with
xylene for 4 mins. All the stained sections were finally mounted with DPX mounting
medium.

2.2.8 Immunostaining and Microscopy Analysis
Brain tissue sections (20 μm thickness) were fixed in acetone-methanol (1:1 v/v)
fixative for 10 minutes at -20°C. This was followed by washing the tissue slides with
PBS, and blocking with 5% bovine serum albumin in 0.1% Triton X-100 PBS at
25°C for 1 hr. Tissues slides were then incubated at 4°C overnight with either of the
following primary antibodies: rabbit anti-Thrombin, rabbit anti-CD42d, rabbit antiCD11b, rabbit anti-NeuN, mouse anti-RIP1, mouse anti-CD68, rabbit anti-ZO-1
(Abcam, Cambridge, MA). After rinses with PBS, sample slides were incubated with
Alexa Fluor 488/594 conjugated with anti-mouse/rabbit immunoglobulin-G (IgG) for
1 hr. After washing with PBS, sample slides were mounted by Golden DAPI
mounting medium (Thermo Scientific, Rockford, IL). For immunohistochemistry
labeling of Coagulation factor XII, a biotinylated rabbit anti-coagulation factor XII
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antibody (Abcam, Cambridge, MA) and streptavidin-HRP were used and amplified
by DAB kit (Thermo Scientific, Rockford, IL). Table 2.1 summarizes the details of
the antibodies, catalogue numbers and dilution factors that were used. Whole brain
tissue section images were scanned (20x magnification) by Leica Aperio Versa 200
digital pathology grade slide scanner, and detailed regional fluorescence images were
captured by a fluorescence microscope (IX81 DSO; Olympus, Somerset, NJ). Cell
counting were performing by using Image J to measure positive stained neurons, and
presented as numbers/ square mm.
2.2.9 Western Blotting
Brain tissues were homogenized on ice using a sonicator with probe, lysed with
CellLytic-M (Sigma) for 30 mins at 4°C, then centrifuged at 14,000 x g. Protein
concentrations from brain tissue homogenates and blood plasma were estimated by
the bicinchoninic acid (BCA) method (Thermo Scientific, Rockford, IL). Protein load
was 20μg/lane in 4-15% SDS-PAGE gradient gels (Bio-Rad, Hercules, CA). The
separated proteins were then transferred onto PVDF membranes, blocked with
superblock (Thermo Scientific), and incubated overnight with the respective primary
antibody listed in Table 2.1 at 4°C, followed by washes and incubation with horseradish peroxidase conjugated secondary antibodies for 1 hr at room temperature.
Immunoreactive bands were detected by West Pico chemiluminescence substrate
(Thermo Scientific). Data were quantified as arbitrary densitometry intensity units
using the Image J software.
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2.2.10 Statistical Analysis
SPSS Statistics 24 software (IBM) was used for all statistical analysis. Data are
presented as mean ± standard error of the mean (SEM, n = 6). Shapiro-Wilk test
revealed no significant deviations from normality in either group, and Levene’s test
for homogeneity of variance revealed no significant differences in variance between
groups. Then between-group comparisons were made by independent t-test to
determine individual group differences. Differences between means were considered
to be significant at the probability level of p < 0.05 or 0.001.

2.3 Results
2.3.1 Brain Infarct Volume and Hemorrhage Increase Dose-dependently in
Fluid Percussion Injury
In previous studies, injury severity was established in the range of mild hemorrhage
(0.5 – 1.4 atm pressure), moderate hemorrhage (1.5 - 2.4 atm pressure), and severe
hemorrhage TBI (> 2.5 atm pressure) in animal models of lateral fluid percussion
injury (FPI) [25]. Brain tissues were removed without PFA perfusion or PBS
washing immediately after injury to examine the extent of hemorrhage and infarct
volume as a proof-of-concept in FPI. Figure 2.1 upper panels showed the tissue
insulted area at the site of impact at different fluid pressure range, and Figure2.1
lower panels revealed the internal hemorrhage and brain infarct in the whole brain
tissue cross-sections compared with control. It was observed that increment of
hemorrhagic lesions and brain infarct volume is related to injury severity. In the
moderate range of FPI, the type of internal injury appeared to be localized in the
injured side of the brain (ipsilateral side) with clear dura membrane damage, but did
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not extent to the non-injured side of brain (contralateral side). In the mild injury level
(0.5 -1.4 atm), the contusion was small with minor visible subarachnoid and
intracranial hemorrhage in the ipsilateral hemisphere. In the severe injury level (> 2.5
atm), the cortex was physically damaged by the fluid pulse with visible intracranial
hemorrhage expanded to the thalamus region and contralateral side. The mortality
rate exceeded 33% at the severe injury level, Figure 2.1 showed representative
images of rats’ brain gross observation, with death right after FPI. The hemorrhage
was significantly larger than other injury levels, and expanded throughout the entire
brain. Here, it was addressed if the infarct volume and hemorrhagic lesions in
moderate injury correlate with the demarcation of coagulation and thrombosis in the
ipsilateral side of the brain. The rationale for selecting moderate injury severity is
that it has a clearly visible brain infarct volume and hemorrhagic lesions with
mortality rate less than 10%, as such, successful preventive measures for such
injuries would be clinically meaningful. The injury in the lower mild pressure range
is not well defined; as such the injury is self-repaired with time perhaps without
compromising the changes in neurocognitive behavior. Mortality rate in the severe
injury type is extremely high; as such it may not be relevant clinically. In Table 2.2,
parameters were summarized for FPI injury severity from the pathophysiological
data collected in this study, and with the incorporation from literature [25]. Thus, 1.82.0 atm was used as the moderate injury working condition for hemorrhage.
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Figure 2.1 Gross observation of the injured brain. Pathomorphological changes in rat
brains at different pressures induced by Fluid Percussion Injury. Source: [98]
Table 2.2 Parameters to Assess Injury Severity Levels for Fluid Percussion Injury.

2.3.2 Bio-distribution of Tracer is Blocked at the Site of Injury
An increase in FITC tracer accumulation was expected at the impact site resulted
from tissue deformation. Thus, large size molecular weight fluorescence tracer
(Dextran, FITC, 2000 kDa) was injected into the CSF via intracisterna magna to
track the bio-distribution of this tracer. The distribution of this tracer in the brain
parenchyma and CSF clearance pathway were examined by whole-brain tissue
sections from sham controls and injured rat brain at different pressure ranges. As
expected, tracer was distributed clearly in subarachnoid space and perivascular space
along the arterial vessels in sham controls and in the very mild range of fluid pressure
injury (Figure 2.2A). But unlike the sham controls, there was no flow through in the
subarachnoid space at the site of impact and surrounding area in moderate pressure
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injury (Figure 2.2A). Figure 2.2B showed a significant difference of tracer
distribution in the perivascular space by enlargement of the contralateral and
ipsilateral cortex. Distribution of the tracer was not observed in the brain interstitial
space due to its large size of the molecule. The combined images of the large
molecule tracer FITC (CSF pathway) with small molecule tracer Texas red (blood
circulation) indicated blood vessel disruption. In the contralateral site, vasculature
was intact with FITC distributed in the perivascular space, but in ipsilateral site,
FITC distribution was blocked and vascular disruption was observed (Figure 2.2C).
Interestingly, the observed blockage area in moderate or severe injury pressure
ranges was correlated to the hemorrhage and infarct volume increment in gross
observation. The temporal and spatial distribution of FITC tracer in sham (Figure
2.3A), moderate FPI at 4 hrs (Figure 2.3B) and 7 days (Figure 2.3C) post-injury
showed a consistent blockage of subarachnoid flow at the injury site, frontal and
caudal site, even though the distances were sectioned about 2.5 mm away from the
injury site (Figure 2.3). The data led us to further investigate if the blockage of tracer
movement in the interstitial space and subarachnoid space was due to coagulation.
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Figure 2.2 Representative image of blockage of FITC (2000 kDa) tracer bio-distribution
in the brain sections. (a)Increased blocked region with FPI pressure increment was
observed. The injury site is indicated by the white arrow. Scale bar: 3 mm. (b) Enlarged
tracer bio-distribution at the contralateral site and ipsilateral site in FPI brain sections.
Scale bar: 500 µm. (c) Merged image of the large molecule tracer FITC (in CSF
pathway) and small molecule tracer Texas red (in blood circulation) in the contralateral
site (Left) and ipsilateral site (Right). T=4 hrs post-injury.
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Figure 2.3 Temporal and spatial distribution of FITC tracer. Rat brain coordinates
indicates the location of tracer distribution at the frontal and caudal site away from
impact site in sham control (a), at 4 hrs (b) and 7 days (c) post-injury. Scale bar is 3mm.
2.3.3 Hemorrhagic Infarct Area and Necroptosis Were Pronounced in the Injury
Side
To evaluate whether blockage of FITC tracer distribution in the subarachnoid and
interstitial was in sync with hemorrhage and hemolytic cell death, the accumulation of red
blood cells (RBC) and necrotic cell death were examined by H&E histological staining as
the first step in injured (Figure 2.4C) and sham brains (Figure 2.4A). H&E staining
validated the localization of hemorrhage indicated by RBC aggregation and hemolytic
cell death in these brain regions (Figure 2.4). Sham control brain tissue section did not
show any of these changes, hemolytic cell death was found around the hemorrhagic area
(yellow arrow in Figure 2.4D) that were identified as the deeply eosinophillic necrotic
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cells that lost their nuclei, while necrosis of small neurons was characterized by
basophilic nuclear pyknosis in H&E staining (blue arrow in Figure 2.4D).

Figure 2.4 Representative H&E staining indicating hemorrhage and cell death after FPI.
(a) Sham, (b) FPI contralateral site and (c) FPI ipsilateral site scale bar is 200 µm. (d)
Enlarged image shows eosinophillic necrotic cells (yellow arrow) & basophilic nuclear
pyknosis (blue arrow) near coagulation, scale bar is 30 µm. T=4 hrs post-injury.
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Figure 2.5 Representative expression of Coagulation factor XII in whole brain sections:
(a: middle panel), injured ipsilateral site (a: left panel), contralateral site (a: right panel),
and sham control whole brain section (c). Scale bar of whole brain section is 2 mm.
Enlarged cortex and hippocampus at ipsilateral site show a significant higher expression
of coagulation factor XII and (b) coagulation in perivascular space (scale bar: 90 µm),
compared with the contralateral site and sham (c). (d) Western Blot shows higher
expression of coagulation factor XII in blood plasma from injured rats than sham control,
collected at T=4 hrs post-injury. Values are mean ±SEM (n = 6), independent t-test,
t(10)=-2.31, *p < 0.05. (e) Immunohistochemistry staining of coagulation factor XII at 7
days post injury shows that coagulation was not cleared. Black arrow shows the blood
vessel with coagulation. Scale bar: 90 µm. Source: [98]
2.3.4 Validation of Tracer Blockage Due to Coagulation at the Injury Site
To evaluate if blockage of tracer distribution in the injured subarachnoid region was
due to coagulation, the possible involvement of specific coagulation factors was
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screened by ELISA kits. Coagulation factor XII and thrombin were highly expressed
out of 14 coagulation factors screened. Expression of coagulation factor XII was
examined in brain tissue sections of injured and sham control animals. Coagulation
factor XII was detected by immunohistochemistry staining in brain tissue sections.
Strong positive expression of coagulation factor XII was observed in subarachnoid
space, brain parenchyma near ventricle and in perivascular space on the injured side of
the brain compared with the non-injured side (Figure 2.5 A-C). This observation
confirmed the notion that blockage of tracer flow in subarachnoid at the injured side
was due to coagulation. The increased levels of coagulation factor XII in blood plasma
(Figure 2.5D) collected in the Luer-lock from injured rats compared with sham
controls further confirmed the argument that an intrinsic coagulation factor XII
formation was a subsequent event of hemorrhage in blunt brain injury. Interestingly,
immunohistochemistry staining of coagulation factor XII showed that coagulation
persisted even at day 7 post-injury (Figure 2.5E). Our results suggest the need for
prevention of coagulation in post-TBI in order to ameliorate the progression of
neurological complication in TBI.
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Figure 2.6 Significantly higher expression of thrombin and blood platelets in the
injured brain than sham or contralateral brain, T=4 hrs. Immunofluorescence staining
of thrombin (a) and CD42d (c) indicate thrombosis and blood platelets adhesion in
the injured brain section, compared with sham. Scale bar is 50 µm. Western Blot
shows higher expression of thrombin (b) in blood plasma and CD42d (d) in brain
tissue from the injured brain than sham. Values are mean ±SEM (n = 6), *p < 0.05.
2.3.5 High Levels of Thrombin and Platelets in Hemorrhagic Area
Since formation of intrinsic coagulation factor XII can lead to extrinsic cerebral
thrombus formation, then the role of thrombin (that converts fibrinogen to fibrin) was
examined and identified by the protein marker for cross-linkage of fibrin clots with
blood platelets. Thus, expression of thrombin and glycoprotein V (by anti-CD42d
antibody) was detected by immunofluorescence staining in whole brain tissue crosssections. Similar to the expression of coagulation factor XII, a positive
immunoreactive staining of thrombin was localized in the subarachnoid space, and
ipsilateral cortex on the injured side compared with the non-injured side (Figure
2.6A). In agreement with the expression of thrombin in the brain tissue, the level of
thrombin in the blood plasma from the injured brain was significantly higher than the
sham control, as shown by Western blot (Figure 2.6B). As expected from thrombin
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results, the levels of the platelets clotting factor marker glycoprotein V (CD42d) in
the brain tissue (Figure 2.6C) or in the brain tissue samples (Figure 2.6D) were
significantly higher in the injured brain than the sham controls.

2.3.6 Necroptosis Is Prevalent around Thrombin Positive Areas
Then the association of coagulation and neuronal cell death was examined in the
hemorrhagic region. Figure 2.7A showed the presence of Cresyl Violet Nissl
staining in sham control (left panel) and absence of Nissl staining in FPI injured
animal (right panel) of whole brain scanned sections. Figure 2.7B-C showed the
enlarged Nissl staining images on the contralateral and ipsilateral side that clearly
indicated the difference in the severity of cell death between the non-injured and
injured brain hemispheres of the same injured animal. To further confirm the necrotic
cell death in such a short-time (4 hrs), receptor-interacting serine/threonine-protein
kinase 1 (RIP1) was used as the marker for necroptosis. Figure 2.8A-B indicated the
significant higher expression of RIP1 at the ipsilateral site in FPI brain section,
compared with the sham brain. Co-localization of NeuN with RIP1 positive cells in
the brain cortex showed necrotic cell death in neurons at the ipsilateral site, compared
with sham control and contralateral site (Figure 2.8C). The evidence of neuronal loss
was validated quantitatively by counting the NeuN positive stained cells in both
sham control and impact site cortex (Figure 2.8D). RIP1 expression was
significantly higher in the injured brain ipsilateral than sham control (Figure 2.8E),
by quantitative analysis of RIP1 protein levels. Our data suggest that necrotic cell
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death arising from coagulation and hemolysis could significantly contribute to
neuronal loss.

Figure 2.7 Neuronal loss shown by Nissl staining at T=4 hrs post-injury. (a) Nissl
staining of whole brain sections for sham control and FPI (scale bar is 3mm).
Enlarged Nissl staining images near the ventricle area (b) and at the impacted cortex
(c) indicates the neuronal cell loss in and around the hemorrhage region at the
contralateral and ipsilateral site. Scale bar in (b) is 300 µm, scale bar in (c) is 200
µm.
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Figure 2.8 Necrotic cell death at T=4 hrs post-injury. Necrotic cell loss was further
examined by RIP1 staining in sham (a) and FPI (b) brain sections (scale bar is 3
mm), as well as the co-localization of RIP1 with NeuN staining (c) (scale bar is 50
µm). (d) Number of NeuN-immunopositive cells in FPI and sham groups. Values are
mean ±SEM (n = 6). **p < 0.001. Western blot (e) of RIP1 show FPI lead to
necrotic cell death at T=4 hrs post injury. Values are mean ±SEM (n = 6),
Independent t-test, t(10)=-2.75, **p < 0.001.
2.3.7 Immune Cells Infiltration at the Site of Hemorrhage
The infiltration and accumulation of immune cells were then investigated by
antibody CD11b and CD68, at the hemorrhage site. CD11b is expressed on the
surface of many leukocytes including neutrophils, monocytes, macrophages and
microglia in the brain, but mostly on neutrophils in the acute stage of the injured

34

brain, with the rounded cell morphology infiltrating through vasculature. Figure
2.9A showed an enhanced infiltration of immune cells in the cortex and around
arterial blood vessels compared with sham controls. CD68 is a protein highly
expressed on the monocytes lineage, including circulating macrophages and tissue
macrophages

(microglia

in

the

brain).

An

increased

infiltration

of

monocytes/macrophages in brain tissue sections was observed from 4 hrs post-TBI
compared with sham controls (Figure 2.8B). The infiltration of immune cells was
seen to be mostly in the hemorrhagic lesions and around the tissue deformed areas, as
depicted by the enlarged CD68 positive area at the actual impact site. These results
suggest that tissue deformation initiated the onsite inflammation of immune cells
because infiltration of immune cells was confined to the hemorrhagic lesions that
penetrated deep down into the ventricle and hippocampus area of the brain. These
data suggest that deformation or even rupture of cerebral vascular integrity may play
an initial vital role for induction of the hemorrhagic inflammatory process,
subsequent coagulative hemolysis, and progression of neurodegeneration in post-TBI.
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Figure 2.9 Aggregation and accumulation of immune cells at 4 hrs after FPI. (a)
Expression of neutrophils by immunofluorescence staining of CD11b in sham & FPI
contralateral and ipsilateral cortex. Scale bar: 20 µm. (b) Expression of
macrophages/monocytes by CD68 immunostaining in sham and FPI whole brain
section. Scale bar: 2 mm. Enlarged image shows accumulated
macrophages/monocytes in the injury site. Scale bar: 20 µm.
2.3.8 Anti-coagulant Treatment Reverses CSF Pathway
As the proof of concept, anti-coagulant drug tissue plasminogen activator (tPA) was
used after FPI, to examine if removal of coagulation can restore the FITC tracer biodistribution in CSF. As anticipated, FITC tracer bio-distribution was restored at the
impact site, and accumulated at the injection site, compared with FPI brain without
treatment (Figure 2.10A). IHC images of coagulation factor XII further confirmed
the clearance of coagulation at the impact site (Figure 2.10A). The anti-coagulant
can be a potential treatment for TBI patients with the clearance of coagulation and
the recovery of CSF pathway.
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Figure 2.10 Anti-coagulant drug reduced coagulation post FPI. Scale bar: 3 mm. (A)
FITC tracer indicated CSF blockage in FPI brain and reverse in tPA treated FPI brain.
(B) Immunohistochemistry staining of Coagulation factor XII in FPI brain and tPA
treated FPI brain. Enlarged image shows the clearance of coagulation by tPA
treatment (scale bar 70 µm). T=3 days.
2.4 Discussion
This discussion will focus on three unique observations post TBI. a) Fluid Percussion
injury is associated with hemorrhagic infarct volume, b) coagulative thrombosis is
developed at the hemorrhagic site, and c) neuroimmune cells activation is prevalent
at the hemorrhagic site as an initial step of inflammation. The findings revealed that
hemorrhage of cerebral vascular and subarachnoid mediated coagulation play an
important role in injury development.
Hemorrhage and subsequent thrombosis management is the severest issue in
emergency care after TBI [81-83], and coagulation can be minimized by resuscitative
care of optimizing cerebral perfusion [99, 100]. This clinical evidence revealed the
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importance of treatment for hemorrhage and thrombosis in TBI. However, effective
care of hemorrhagic bleeding and coagulative thrombosis in TBI patients remained
challenging, partly due to uncovering the elusive mechanisms. Thus, the distinctive
findings of intracranial hemorrhage, CSF pathway blockage, necrosis and immune
cells infiltration observed in the present study appeared to be in sync with clinical
observations in neurotrauma patients in critical emergency care [81-83].
The “dose-dependent” related internal hemorrhage with infarct volume
immediately post-injury (Figure 2.1) was a clear indication of physical tissue
damage impacted by mechanical force. Similar intraventricular hemorrhage and
thrombin level increase post-TBI in moderate rat LFPI was shown by Lyeth’s group
[101]. They found that activation of Src kinase signaling pathway caused by
thrombin results in hippocampal neuronal loss and cognitive dysfunction. However,
the importance of hemorrhage associated coagulation and subsequent necrotic cell
death in Figures 2.4 and 2.5 had not been well documented in experimental FPI
model. Necrotic cell death was examined in Figure 2.8 by the presence of RIP1,
which was a necroptosis marker [102, 103] around the brain area of hemorrhage and
coagulation sites, and this neurotoxic necroptosis could be contributed by elongated
coagulation as shown in Figure 2.5 and Figure 2.6. Further investigation of other
necrosis marker, RIP3 and MLKL are needed to confirm the pathway of necrosis.
Recently, an early impairment of pericyte-endothelium interaction was
demonstrated to result in BBB dysregulation in a FPI model [75]. And the dynamics
of T-cell infiltration into brain parenchyma post FPI was shown to be a contributing
factor to post-injury impairment and poor recovery [104]. Moreover, age is another
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important factor for TBI experimental model. It was found that most TBIs occur in
males among the adult population [105], and age can determine the survival rate
following isolated TBI [106], by resulting in more severe secondary brain damage
[107], increased neuroinflammation with significantly higher monocytes infiltration
[108], and age-dependent production of inflammation cytokines and chemokines
[109]. Thus 8-10 weeks male rats were used in this study, to replicate human adult
TBI scenario and reduce the age-dependent effects on inflammation response.
Further, the event of hemorrhage and coagulation is capable of triggering the
activation of microglial cells as seen in Alzheimer’s disease [110]. These unchartered
events of hemorrhage and coagulation at post-injury are likely to bridge the missing
piece for proper management of TBI related neurological disorders, because
cerebrovascular damage, hemorrhage, and pro-inflammatory clotting factors are
found to be closely associated with neurological diseases like Alzheimer’s disease
[111, 112]. Therefore, preventive measure targeting cerebrovascular disruption and
coagulation in post-TBI could potentially serve as regenerative approach to slow
down the progression of neurological disease in TBI. To this end, the present
findings may bridge the knowledge gap between clinical observations and animal
studies for a successful therapeutic treatment in TBI patients.
These findings also shed important light on immune cells infiltration and glial
cells activation as the secondary mechanisms of neuroinflammation and
neurodegeneration post TBI. The infiltration of immune cells was mostly localized in
hemorrhage and coagulative area and penetrated deep inside the ventricle and
hippocampus area similar to the track path of infarcted brain volume. These data
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suggest that neuroinflammation and neurodegeneration in the demarcated brain area
were initiated by hemorrhage and aftermath coagulation. The significant aggregation
of immune cells around the hemorrhagic region where the arterial vessels (the BBB)
were ruptured, further validated the point that hemorrhage and coagulation regulated
the immune cell infiltration, neuroinflammation and neurodegeneration post-TBI. It
is strongly suggested here that proper management of coagulation at the site of injury
may promote hemorrhagic wound healing, prevent neuronal loss, and should be
considered for post-TBI therapeutic treatment.
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CHAPTER 3
OXIDATIVE/NITROSATIVE DAMAGE MEDIATED CEREBRAL
VASCULAR INFLAMMATION AND NEURODEGENERATION AFTER
TRAUMATIC BRAIN INJURY
3.1 Introduction
Traumatic brain injury (TBI) can be described as a physical intracranial injury which
occurs when there is an external mechanical force, including impact, blast wave,
penetration and sudden acceleration-deceleration [60]. About 10 million people are
affected by TBI worldwide, and 5.3 million people experience TBI in the USA [2].
Most of the TBI cases are caused by motor vehicle accidents, falls and strikes or
blows to the head, such as sports injuries or blast injuries [18, 113]. TBI leads to
physical, cognitive and behavioral impairment, and a high risk of the later
development of neurodegeneration, including Alzheimer’s disease (AD) [10, 15-17].
Over the past decades, despite there have been numbers of phase III clinical trials, no
treatment has been shown to be efficacious [21, 22].
Disruption of blood brain barrier (BBB) is found to be involved in TBI and
neurological disorders [75, 76, 114]. Some studies have shown that the induction of
free radical generating enzymes, oxidative damage, and BBB leakage are the main
factors leading to perivascular inflammation [115, 116]. Reactive oxygen species
(ROS) are the major sources of oxidative stress in brain injury, including superoxide
(O2-), hydroxyl radical (HO-), hydrogen peroxide (H2O2), and hypochlorousacid
(HOCl) [117]. Superoxide causes tissue damage by promoting hydroxyl radicals
from hydro-gen peroxide (H2O2) and peroxynitrite (−ONOO) when combined with

41

nitric oxide (NO). RNS includes NO and the product of NO, O2− and peroxynitrite
(ONOO−) [117]. It was demonstrated that the production of ROS/RNS is
significantly enhanced by TBI [118]. ROS/RNS can further accumulate the condition
and lead to BBB disruption via degradation of the extracellular matrix and tight
junction proteins, and activates caspase-1/3, resulting in cell apoptosis [119].
Moreover, ROS/RNS also activate different inflammatory cytokines and growth
factors such as IL-1β, IL-6, and TGF-β [120], which further aggravate
neuroinflammation in TBI.
Interestingly, neuropathological analysis [67] of postmortem brains from young
athletes revealed a significant neurodegeneration in the form of phosphorylated tau
protein localized around the perivascular region. This distinctive localization of tau
neuropathy around perivascular region showed evidence that vascular BBB oxidative
injury and inflammation may lead the foundation for neuroinflammation initiation
and neuronal degeneration propagation within the neurovascular layers. Growing
evidence suggests that microvascular damage is involved in neuropathogenesis of
TBI and Alzheimer’s disease [121]. A number of studies have demonstrated that
microglial activation is found in the brains of TBI patients and in the animal models
of TBI [122]. It has been demonstrated that activated microglia also produce reactive
oxygen species (ROS) such as superoxide (O2-) and O2- derived oxidants, which may
induce or exacerbate neurotoxicity by causing oxidative stress to neurons [123].
From previously published data of our laboratory, oxidative damage of the
blood-brain barrier (BBB) was found to be the major mechanism of TBI in blast
wave animal model [124]. The present study examined the temporal changes of the
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NADPH oxidase (NOX) 1 and inducible nitric oxide synthase (iNOS), as well as
levels of superoxide/nitrosative and formation of protein adducts 4-hydroxynonenal
(4-HNE) and 3-Nitrotyrosin (3-NT). Cerebral vascular oxidative damage is
associated with reduction in the BBB tight junction proteins and enhanced immune
cell infiltration through perivascular units [116]. Thus destruction of the barrier leads
to neuroinflammation and neurodegenerative disease [116].
Microglial

activation

was

examined

in

this

chapter

to

identify

neuroinflammation footprint, especially for the M1 pro-inflammatory state at
different time points. M1 phenotype is the pro-inflammatory state that releases
cytokines, chemokine and ROS/RNS which further exacerbate neural injury. M2
state is related to a phagocytic role and the release of neurotrophic factors that
promote repair and [125, 126].

But it is rare to specify M1 or M2 microglial

phenotypes in chronic diseases, since these states are transitory and commonly mixed
[127]. In this study, M1 phenotype was examined as the pro-inflammatory phenotype
lies at one extreme of the reactivity spectrum, and can contribute to chronic
neuroinflammation and long-term neurological impairments [128]. Co-localization of
IBA-1 with RNS generation enzyme iNOS and pro-inflammatory/anti-inflammatory
cytokine IL-6 was attempted to indicate the M1 phenotype of microglia at 4 hrs and 7
days post FPI. IL-6 is an interleukin that acts as both a pro-inflammatory cytokine
and an anti-inflammatory myokine, and it has been established as a marker to
identify M1 phenotype of microglia in rats [128-130].
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3.2 Methods and Materials
3.2.1 Fluid Percussion Injury
All the use of experimental animals and Fluid Percussion injury model protocol was
same as described in Chapter 2.2 Methods.
3.2.2 Real-time NO and Superoxide Detection
The method for free radical analysis in brain tissue was established in the previous
study [131]. Freshly isolated brain tissues was prepared in ice-cold oxygenated (95%
O2 and 5% CO2) artificial cerebrospinal fluid (aCSF). NO/O2- was measured using
free radical analyzer with a specific NO or O2- probe (TBR4100, World Precision
Instruments, Sarasota, FL). The probe is able to polarographically measure the
concentration of NO/O2- in solutions. The NO detection system was calibrated daily
using different concentrations of NO donor S-Nitroso-N-acetyl-DL-penicillamine
(SNAP) to generate a standard curve, and the O2- detection system was calibrated
using different concentrations of H2O2 solution. Baseline of NO/O2- release was
determined by evaluation of NO/O2- release in aCSF without any treatments. The
concentration of NO/O2- in solution was measured in real time. Each experiment was
simultaneously performed with a control brain to exclude experimental drift in
NO/O2- release unrelated to the study.

3.2.3 Tissue Processing
At different time points after TBI, the rats were deeply anesthetized and euthanized
via slow transcardiac perfusion with ice cold phosphate buffered saline (PBS),
followed by ice cold 4% paraformaldehyde in PBS. Brain areas involved in the
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traumatic foci were recut from the whole brain and immersed in 4%
paraformaldehyde overnight, followed by cryoprotection in 30% sucrose containing
PBS. Coronal sections of 10μm thickness were sectioned from each sample and
stored at −80°C for further analysis.

3.2.4 Immunofluorescence and Microscopy
This procedure was same as described in Chapter 2.2 Methods. Cell counting were
performing by using Image J to measure positive stained Neurons, and presented as
numbers/ square mm.

3.2.5 Western Blotting
This procedure was same as described in Chapter 2.2 Methods. All information about
the source of antibodies, intended biomarker, catalogue numbers, and dilutions
factors for immunohistochemical staining and western blotting analyses are listed in
Table 3.1. Densitometry analysis of target marker was performed in a blinded way
using ImageJ software. The levels of the marker detected are normalized with β-actin
as loading control as a ratio.
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Table 3.1 Antibody Source, Catalogue Numbers, and Dilution Factors for
Immunohistochemical Staining and Western Blott Analysis

3.2.6 Statistical Analysis
All results are expressed as the mean ± SEM. Statistical analysis of the data was
performed using GraphPad Prism 7(Sorrento Valley, CA, USA).

Comparisons

between samples were performed by one-way ANOVA with Tukey’s multiple
comparison tests, two-way ANOVA with Sidack’s multiple comparisons test, and
independent t-test. Differences were considered significant at *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
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3.3 Results
3.3.1 Free Radicals Generation Increases Significantly Post TBI
Real-time free radicals production of the injured brain tissue was first examined by a
free radical analyzer. Reactive oxygen species (ROS) superoxide (O2-) and reactive
nitrogen species (RNS) nitric oxide (NO) were investigated at different time frames,
including immediately after FPI (0 hr), after 4 hrs and 7 days post FPI, compared
with sham control brain (Figure 3.1). Each brain tissue was also separated into the
ipsilateral and contralateral site, to compare the injured hemisphere with non-injured
hemisphere. Two-way ANOVA was used to compare each time frame as well as the
ipsilateral and contralateral site within each group. For NO generation (Figure 3.1A),
significant differences were found when compared 0 hr, 4 hrs brain tissue with sham
and 7 days brain tissue post FPI (F (3, 24) = 165.4, p<0.0001). And ipsilateral site
had significant higher generation of NO at 0 hr and 4 hrs, when NO was reduced
after 7 days post FPI in the injured brain (F (1, 24) = 127.1, p<0.0001). Meanwhile,
Superoxide generation was significant higher in the ipsilateral site, at 0 hr, 4 hrs and
7 days post FPI (F (3, 15) = 39.78, p<0.0001). At 0 hr and 4 hrs post FPI, superoxide
expression was much higher in the ipsilateral site compared with contralateral site (F
(1, 15) = 395.9, p<0.0001). Even though O2- generation was reduced, it still showed a
significant difference with sham group at day 7 post FPI (Figure 3.1B).
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Figure 3.1 Nitric oxide and hydrogen superoxide generation at different time post
FPI. Real-time NO (A) and O2- (B) production were detected in live rat brain tissue
by Free Radical Analyzer. Live brain tissues were cultured in oxygenated CSF.
Values are mean ±SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 versus
sham (N = 7).
3.3.2 Oxidative/Nitrosative Damage in Perivascular Space and Propagated after
Injury
To further examine the oxidative/nitrosative stress, the ROS/RNS generating
enzymes were investigated by NADPH oxidase 1 (NOX1), and inducible nitric oxide
synthase (iNOS), respectively. Corresponding oxidative damage marker 4Hydroxynonenal (4-HNE), and nitrosative damage marker 3-Nitrotyrosine (3-NT)
were examined in parallel with the enzyme markers. Significant higher expression of
iNOS (Figure 3.2A) and 3-NT (Figure 3.2B) were observed in the ipsilateral site at
4 hrs post FPI. By co-localization of 3-NT with tight junction protein Zonula
occludens-1 (ZO-1), it showed that nitrosative damage occurred in blood brain
barrier at 4 hrs post FPI (Figure 3.2C). Western blot results showed the
quantification analysis of iNOS and 3-NT in sham and the ipsilateral site at 4 hrs, 3
days and 7 days post FPI. Significant increase was found at 4 hrs for both RNS
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generating enzyme and nitrosative stress marker, and then they both decreased after 3
days and 7 days (Figure 3.2D-E). There was no significant difference between 3
days/7 days post FPI with sham control.
ROS generating enzyme NOX-1 and oxidative stress marker 4-HNE was
evaluated by immunostaining and western blot, respectively (Figure 3.3). Increased
expression of NOX-1 and 4-HNE was observed in the ipsilateral site, compared with
sham and the contralateral site at 4 hrs post FPI. With co-localization of tight
junction protein claudin5, oxidative stress was found in blood brain barrier.
Interestingly, even though both oxidative/nitrosative enzymes and stress markers
showed similar trends with a decrease after 3 days and 7 days post-FPI, the ROS
generation enzyme NOX1 and damage marker 4-HNE in injured brain at day3 and
day7 were still significantly higher than sham control.
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Figure 3.2 FPI induced nitrosative stress in the blood brain barrier. (A) shows RNS
generation enzyme iNOS expression in sham, injured brain contralateral and
ipsilateral site at 4 hrs post FPI, (B) is the nitrosative stress marker 3-NT staining in
the injured brain contralateral and ipsilateral site, compared with sham brain at 4 hrs
post FPI. (C) Co-localization of 3-NT with tight junction protein Zonula occludens-1
in the injured brain contralateral and ipsilateral site, compared with sham brain at 4
hrs post FPI. Scale bar is 20 µm. (D) and (E) are western blot results of iNOS and 3NT, in sham brain and injured brain ipsilateral tissue after 4hrs, 3 days and 7 days
post FPI, respectively. Values are mean ±SEM, one-way ANOVA was used, F(3,
20)=18.15, **p<0.01, ***p<0.001, versus sham (N = 6).
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Figure 3.3 FPI induced oxidative stress in the blood brain barrier. (A)ROS
generation enzyme NOX1 expression in sham, injured brain contralateral and
ipsilateral site at 4 hrs post FPI, (B) Representative Immunostaining of 4-HNE in
sham, injured brain contralateral and ipsilateral site at 4 hrs post FPI. (C) Oxidative
stress marker 4-HNE co-localized with tight junction marker Claudin-5 in sham,
contralateral and ipsilateral brain. Scale bar is 20 µm. (D) and (E) are western blot
results of NOX1 and 4-HNE, in sham brain and injured brain ipsilateral tissue after
4hrs, 3 days and 7 days post FPI, respectively. Values are mean ±SEM. One-way
ANOVA was used, F(3, 20)=25, *p<0.05, **p<0.01, ***p<0.001, versus sham
(N = 6).
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3.3.3 Cerebrovascular Disruption and Immune Cells Infiltration
Blood brain barrier (BBB) integrity and immune cell reactions were then examined at
the hemorrhage site after 4 hrs and 7 days post FPI. Antibody to CD11b and CD68
were used for detection of immune cells, as described in Chapter 2.3 Results. Colocalization of CD11b with tight junction protein Occludin in Figure 3.4 showed an
enhanced acute aggregation of CD11b positive cells through BBB at 4 hrs post-FPI,
in injury site compared with sham control. An increased infiltration of CD68 positive
cells (monocytes/macrophages) through BBB was also observed in brain tissue
sections at 4 hrs post-TBI compared with sham controls (Figure 3.5). Interestingly,
co-localization of the blood-brain barrier tight junction anchoring protein zonula
occluden-1 (ZO-1) with CD68 indicated a significant aggregation of monocytes or
macrophages around perivascular space in the injured brain tissue compared with
sham controls (Figure 3.5C).
At 7 days post FPI, immune cells were still significantly accumulated at the
impacted site, and infiltrated through BBB (Figure 3.6). CD11b positive immune
cells were observed in the ipsilateral site (Figure 3.6A), co-localization of CD68
with ZO-1 at 7 days post-FPI showed the monocytes/macrophages infiltration
through BBB (Figure 3.6A). These evidence indicated the prolonged immune
reactions after TBI, paralleled with BBB disruption.
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Figure 3.4 CD11b positive immune cells infiltration at 4 hrs post FPI. Tight junction
protein occludin (A) and CD11b (B) in sham, FPI brain contralateral site and
ipsilateral site. (C) Co-localization of CD11b with occludin shows CD11b positive
cells infiltration through BBB. Scale bar is 20 µm.
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Figure 3.5 CD68 positive immune cells infiltration at 4 hrs post FPI. (A) Tight junction
protein ZO-1 and pan-macrophages marker CD68 (B) in sham, FPI brain contralateral
site and ipsilateral site. (C) Co-localized images indicate the infiltration of CD68 positive
immune cells through blood brain barrier. And BBB integrity was impaired. Scale bar is
20 µm.

Figure 3.6: Prolonged immune cells accumulation at 7 days post FPI. (A) Representative
image for CD11b positive cells in sham, FPI brain contralateral and ipsilateral site. (B)
Co-localization of CD68 (green) with ZO-1 (red) indicates the persistent aggregation of
monocytes/macrophages through blood brain barrier. Scale bar is 50 µm.
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3.3.4 Microglial and Astrocytes Activates after Traumatic Brain Injury
As the resident macrophages in the brain, microglia were expected to react to acute
immune cell infiltration and hemorrhage. And astrocytes may also be activated to aid
in the maintenance of the BBB. Thus gliosis was examined after FPI by GFAP (Glial
fibrillary acidic protein) and IBA-1 (ionized calcium binding adaptor molecule-1) as
the markers for astrocytes and microglial, respectively. In Figure 3.7, microglial and
astrocytes were activated at 4hrs post FPI, especially in the cortex and around BBB at
the ipsilateral site. By comparison with sham brain sections, GFAP and IBA-1
positive cells were highly expressed in the ipsilateral site (Figure 3.7A-B). In the
merged images of GFAP and IBA-1, increased astrocytes and activated microglia in
amoeboid form were observed in the ipsilateral site, surrounding BBB and in the
impact cortex (Figure 3.7C).
To further investigate the phenotype of microglia at different time points post
FPI, iNOS and IL-6 were used for co-localization with IBA-1, to identify M1
phenotype at different time points post FPI. In Figure 3.8, IBA-1 positive cells were
found to be significantly co-localized with iNOS at the impact site and in the
ipsilateral cortex at 4 hrs post FPI. After 7 days post-FPI, with the reduction of RNS
enzyme iNOS and decreased amoeboid microglia, the co-localization of IBA-1 with
iNOS was difficult to observe. Meanwhile, microglia remained inactivated form in
the contralateral site at both 4 hrs and 7 days post FPI.
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Figure 3.7 Microglia and astrocytes active after FPI. (A) - (B) show whole brain
section for microglia (IBA-1) and astrocytes (GFAP) activity in sham and FPI brain
sections at 4 hrs post FPI. White arrow indicates the injury site. Scale bar: 3 mm. (C)
Merged images of IBA-1 and GFAP in sham, contralateral, ipsilateral site-blood
brain barrier and cortex. Activated microglia and astrocytes are highly presented
around blood brain barrier and at injured site compare with sham and contralateral
site. White arrow head indicates the amoeboid form of microglia. Scale bar: 20 µm.
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Figure 3.8 Co-localization of IBA-1 (green) with inducible nitric oxide synthase
iNOS (red) at 4 hours and 7 days post-FPI. Merged images in sham (A), FPI 4hrs
brain impact site (B), 4 hrs (C-D) and 7 days (E-F) in the ipsilateral and contralateral.
Scale bar is 60 µm.
In the current study, IL-6 was highly expressed in the ipsilateral site at 4 hrs post FPI,
compared with sham and contralateral site, and reduced but still substantially
expressed in the ipsilateral site after 7 days. Meanwhile, the number of amoeboid

57

microglia was decreased after 7 days post FPI, so were the co-localized microglia
with IL-6 (Figure 3.9).

Figure 3.9 Co-localization of IBA-1 (green) with Interleukin 6 (IL-6, red) at 4 hours
and 7 days post-FPI. Merged images in sham (A), enlarged amoeboid microglia
expressing IL-6 (B) at 4 hrs at the impact site, 4 hrs (C-D) and 7 days (E-F) in
ipsilateral and contralateral. Scale bar for A, C-F is 60 µm, for B is 30 µm.
3.3.5 Tau-protein Phosphorylation and Apoptosis after Brain Injury
To track cell death following neuroinflammation, immunofluorescence staining was
used for apoptosis marker Caspase-3. Caspase-3 was upregulated in the ipsilateral
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site, indicating the ongoing programmed cell death at 7 days post FPI (Figure 3.10GI). Tauopathy was also investigated as an indication of neuronal dysfunction, as the
phosphorylated tau can induce microtubule instability that results in cell death.
Hyper-phosphorylation of tau protein was found in perivascular space, and
accumulated surrounding vasculature structure (Figure 3.10). Western blot showed
quantification results of total tau protein marker Tau-5 and phosphorylated tau
protein marker Ser202 (Figure 3.10J-K). Both of them peaked at 4 hrs post FPI, then
decreased after 3 days post FPI, and only 4 hrs was significantly different to sham.
NeuN immunostaining was then used to indicate the neuronal loss in the
injured cortex site at day 7 post FPI (Figure 3.10). By qualitative staining images
and quantitative positive NeuN cell counting, significant neuronal loss was observed
at day 7 in the injury site.
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Figure 3.10 Tauopathy and apoptosis after FPI. Co-localization of phosphorylatedtau Ser202 (phf-tau) (red) & Caspase-3 (green) in sham (A-C), FPI contralateral (D-F)
and ipsilateral (G-I) brain after 7 days post FPI. Bright field image in (C) was taken
at the same region of the immunostaining image in the same brain section. Scale bar:
20 µm in A-I. (D-E) show western blot results for total-tau protein Tau-5 and phf-tau
Ser202 at different time point in the ipsilateral site, compared with sham control.
Values are mean ±SEM. One-way ANOVA was used, F(3, 20)=30, ***p<0.001,
versus sham (N = 6).
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Figure 3.11 Neuronal loss in the injured cortex after 7 days post FPI. (A)
Representative immunostaining of NeuN in sham and FPI injury site. Scale bar is 50
µm. (B) Neuronal cells counting in cortex for NeuN staining in sham and FPI injury
site cortex. N=12. **p < 0.01.

3.4 Discussion
In the present study, oxidative/nitrosative damage was examined in blood brain
barrier at the injury site, followed by the prolonged gliosis, cytokine release, immune
cells accumulation, apoptosis, tauopathy and neuronal loss. The nature of sustained
cerebrovascular disruption was oxidative/nitrosative damage, which might be
initiated by ROS/RNS via the induction of NOX1 and iNOS. The signature of
oxidative damage (4-HNE) and nitrated protein (3-NT) in the vasculature was
correlated with the induction of NOX1/iNOS. The expression of these markers both
peaked at 4 hrs post FPI and reduced after 3 days post FPI. In the context of these
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findings, it was emphasized that cerebrovascular oxidative injury may precede the
development of neuroinflammation.
From previous studies in our group, the authors have reported BBB leakage
with the evidence of tight junction protein disruption (occludin, claudin-5, and zonula
occludin 1) post mild TBI in primary blast animal model [119]. Recently from
Chandra’s group, a thorough investigation of cell-type dependent increase in NOX
isoforms at different brain regions was reported in the blast shock-wave rodent model
[132]. Oxidative damage has been found not only in BBB [133, 134], but also in
neurons, astrocytes and microglia. As the future direction for blunt TBI, it will be
beneficial to examine the cell-type dependent increase of ROS/RNS.
Meanwhile, zonula occludin 1 (ZO-1) and occludin were used as the tight
junction protein markers to investigate BBB integrity. When co-localized with
immune cells marker CD68 and CD11b, the results indicated a significant
aggregation and accumulation of neutrophils, monocytes and macrophages from
blood circulation to the brain parenchyma, as well as impairment of tight junction
proteins. In the previous study, our group reported the acute immune cells infiltration
at 4 hrs post FPI [135], which causes inflammation as the secondary event following
vascular rupture and hemorrhage. Here, it was further indicated that after 7days post
FPI, the infiltration of immune cells was prolonged. It was probably resulted from the
persistent oxidative damage in the BBB and the vascular disruption.
In response of immune cells accumulation, microglial activation was observed
at 4 hrs and 7 days post FPI at the injury site. Microglia phenotypes can be identified
by co-localization with other markers [129], here, iNOS and IL-6 were used as M1
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phenotype markers. A significant co-localization of IBA-1 positive cells with iNOS
was observed at the impact site at 4 hrs post FPI (Figure 3.8B), nevertheless, some
of the IBA-1 positive cells were round shape, which should be monocytes and were
unlikely to be microglia. To separate these two types of cells, further study is needed
with the use of CD45 for monocytes [125]. The number of amoeboid microglia was
reduced after 7 days post FPI, but still substantial in the ipsilateral cortex, showing a
prolonged inflammation and the process of phagocytosis to clear cell debris and
coagulation. However, the conclusion cannot be made that M1/M2 phenotypes
changed in temporal, previous studies reported the uncertainty that microglia have
both phenotypes in acute and long-term post TBI [125, 129, 136].
With the finding of the prolonged neuroinflammation, as a result,
neurodegeneration happens following the events of inflammation. In deed, the
current findings validated that Caspase-3 activation and cell apoptosis were observed
mostly around the perivascular region of the brain, suggesting the ongoing apoptosis
in parallel with gliosis and immune cells infiltration after 7 days post FPI. Moreover,
the significantly higher phosphorylation of tau protein around perivascular space
showed the indication of neurodegeneration and can be a hallmark of injury
pathology. Interestingly, phosphorylated tau protein Ser202 and total tau Tau-5 were
both found to increase significantly at 4 hrs post FPI and return to sham level after 3
days and 7 days in the current study, while tauopathy is the hallmark for chronic
traumatic encephalopathy (CTE) which is typically found after months or even years
post TBI [11, 71]. But similar trends of results were also reported in other studies for
rapid accumulation of tau oligomers in FPI model [136, 137]. The evidence of acute
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accumulation and reduction after 3 days for tau/phosphorylated-tau, could be
paralleled with the pattern of oxidative damage, and the gliosis in this study. In the
recent years, microglial activation has been well established that it is tightly
associated with prolonged neuroinflammation and neurodegeneration in CTE,
Alzheimer’s disease and Parkinson’s disease [111, 136, 138, 139]. With the current
finding of microglial robust M1 phenotype at 4hrs and prolonged amoeboid form
after 7 days post TBI, it can be postulated here that the acute tau
hyperphosphorylation is likely to be associated with gliosis and oxidative damage.
The immune system may attempt to protect CNS and clean the neurotoxic debris/
waste metabolites in short-time, but fail in long-term with the sustained
neuroinflammation and thus lead to chronic neurodegeneration.
All together, these findings in the current study validated the correlation of
oxidative/nitrosative damage with cerebrovascular disruption in moderate FPI model,
as well as the secondary injury propagated as the prolonged neuroinflammation and
neurodegeneration in longer term.
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CHAPTER 4
REGENERATIVE TREATMENT WITH ANGIOGENIC SELF-ASSEMBLING
PEPTIDE HYDROGEL
4.1 Introduction
A major concern of traumatic brain injury (TBI) is the direct damage to the cerebral
vasculature. Hemorrhage, blood–brain barrier (BBB) disruption, edema, and blood
flow abnormalities occur in the early stage following the insult, these are commonly
observed in TBI patients and recapitulated in animal models of TBI [77, 78, 81]. At a
cellular level, the cerebral vasculature contributes several key components to the
expanded neurovascular unit (eNVU), consisting of endothelial cells, smooth muscle
cells, neurons, astrocytes, and pericytes [75]. Disruption of the vascular tree precedes
ischemia, immune cell infiltration, altered delivery of metabolites, hypoxia and tissue
death [85]. These suggest that treatments which promote neoangiogenesis of mature
and stabilized vessels, may allow enhanced recovery for TBI.
Clinical trials in TBI to date have not specifically targeted angiogenesis and
neurogenesis in situ [140]. Preclinical studies in cerebral ischemia are replete with
strategies that deliver vascular endothelial growth factor, sildenafil, atorvastatin,
carbamylated erythropoietin (EPO) and EPO monotherapy, to name a few [141-146].
Treatments with growth factors also contribute to eNVU remodeling, improving
outcomes after ischemic brain injury [146]. However, these systemic or local
treatments are cleared by the body in a matter of minutes to hours and do not have a
durable localized effect. Further, few strategies report the generation of a supportive
in situ microenvironment for wound healing [147]. In previous studies, Kumar’s
group have generated a self-assembling peptide hydrogel (SAPH) appended with a
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potent mimic of VEGF-165, QK [148]. Vascular endothelial growth factor (VEGF) is
angiogenic and neuroprotective that can promote neurogenesis in the repair process
after brain injury [149-152]. This angiogenic peptide hydrogel termed SLanc,
assembles into fibers displaying the QK epitope in very high density [148, 153-159].
Owing to non-covalent interactions, these peptides rapidly assemble and dissemble
upon needle shear. Injectable gels have been examined in in vitro assays for
cytocompatibility, angiogenesis, recovery from hind limb ischemia, and management
of a number of ischemic tissue diseases [153-155].
In the current study, the angiogenic SAPH termed SLanc was tested in the
impact site post FPI, for its angiogenic and neuroprotective effect in the injured rat
brain. A lateral fluid percussion injury model (FPI) was used to induce a moderate
blunt TBI, with physical vascular disruption and tissue deformation [94]. SLanc
peptide hydrogels were injected into the injury site immediately after FPI, and the
bio-distribution along with histological recovery (angiogenesis and neuronal
survivability) were evaluated at day 7 and day 14 post injury.

4.2 Methods and Materials
4.2.1 Synthesis and Characterization of Peptides
SLanc was designed and prepared by Dr. Vivek Kumar’s laboratory. It was prepared as
previously described [148, 155]. Briefly, SLanc was synthesized by a standard Fmoc
solid-phase peptide synthesis protocol and purified through dialysis against DI water
for 2 days. The dialyzed peptide was frozen, lyophilized and stored in the powder form
at –80°C until formulation. The peptide hydrogel was prepared initially at a
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concentration of 20 mg/ml (2 w. %) in sterile 298 mM sucrose with pH adjusted to 7.
To obtain the final concentration of 10 mg/ml, the same volume of sterile 1X HBSS
sucrose solution was added. This formulation was easily injectable with a 25G needle.
Table 4.1 Primary Sequences of Peptides Used in this Study
Name

Sequence

SLanc

K(SL)3RG(SL)3K–G–KLTWQELYQLKYKGI

F-SLanc

Carboxyfluorescein-K(SL)3RG(SL)3K–G–KLTWQELYQLKYKGI

4.2.2 Cytocompatibility of SLanc on Primary Neurons
1% (w/v) SLanc was placed into the wells of a 96-well plate (100 µL/well) and
incubated at 37oC for 2 hrs to gel. Complete neurobasal medium containing 2% Gibco
B27 supplement with antioxidants (50X), 1% penicillin-streptomycin, and 0.2%
glutamate was added and incubated at 37oC for 2 hrs to condition the SLanc. Primary
neuronal cells were obtained by neuronal isolation. Briefly, cortices were extracted
from the embryos of a Sprague Dawley pregnant rat (Charles River) at day 16 gestation.
Cortices were then digested in trypsin-EDTA (0.25%) at 37°C for 30 mins. Primary
cortical neurons were separated by straining with 70 µm and 40 µm pore filters.
Neurons were seeded at a density of 50,000 cells/cm2 on top of the SLanc and
supplemented with complete neurobasal medium. Cell morphology and neurite growth
was observed over time by microscopy.
4.2.3 Animal Handling
Adult male and pregnant female Sprague-Dawley and Wistar rats were purchased from
Charles River Laboratory (Wilmington, MA). The animals were kept with free access
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to food and water in a 12 hrs dark-light cycle at room temperature. All procedures were
followed in accordance with guidelines established in the Guide for the Care and Use of
Laboratory Animals and were approved by the NJIT-Rutgers-Newark Institutional
Animal Care and Use Committee.

4.2.4 Fluid Percussion Injury
Sprague Dawley male rats (250-300 g; 8–11 weeks old) were randomly selected and
subjected to lateral FPI for a moderate TBI [25]. Sham-injured cases served as control.
5 rats were used for each group (Sham, FPI+PBS, FPI+SLanc). All rats were
anesthetized with a mixture of ketamine (100 mg/kg), and xylazine (10 mg/kg)
administered via intraperitoneal injection and placed in a stereotaxic frame. Craniotomy
(3.0 mm) was performed over the left parietal skull, 2.5 mm lateral from the midline
and 3.0 mm caudal from bregma, with the dura intact. A Luer-lock hub was positioned
according to the craniotomy and secured with cyanoacrylate gel on the skull. The hub
was secured by application of methyl-methacrylate (Henry Schein, Melville, NY, USA).
One day after surgery, animals were randomly selected to receive either sham or FPI.
Sham animals were subjected to all surgical procedures except the induction of the
injury. For induction of FPI, the pendulum hammer was released onto the piston of the
fluid filled cylinder to induce a water pulse. For a moderate injury (1.6-1.8 atm.), the
recorded apnea and righting reflex time were 10-12 s and 6-8 min, respectively.
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4.2.5 Therapeutic Intervention and Bio-distribution of Peptide
After FPI and anesthesia, the rats were placed in a stereotaxic frame to be treated with 5
µl SLanc peptide hydrogel, Fluorescent-tagged SLanc peptide, or PBS as the injury
control. The location of injection according to the stereotaxic coordinates was: AP= -3,
L= -2.5 from Bregma, dorsoventral (DV) = 0.5 mm. Then the injury hub was removed,
and the head was sutured. The rats recovered on a heating pad and then they were
returned to their cage.

4.2.6 Tissue Processing
3, 7, 14 days after FPI/FPI + treatment, the rats were euthanized via slow transcardial
perfusion with ice cold phosphate buffered saline (PBS), followed by ice cold 4%
paraformaldehyde in PBS. Brain tissues were immersed in 4% paraformaldehyde
overnight, followed by cryoprotection in 30% sucrose containing PBS. 20 μm thick
coronal sections were processed from each sample and stored at −80°C for further
analysis.

4.2.7 Immunofluorescence and Microscopy
Both in vitro and in vivo constructs were analyzed through immunofluorescence.
Coverslips with cells were fixed in 4% paraformaldehyde for 15 mins at room
temperature, followed by washing with 0.1% Triton X-100 in PBS for 5 mins at
room temperature. Brain tissue sections were washed with PBS and fixed in acetonemethanol (1:1 volumetric ratio) for 10 mins at –20°C for immunofluorescence
staining. Fixed slides were then blocked with 3% bovine serum albumin at 25°C for 1
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h in the presence of 0.1% Triton X- 100. Slides were incubated with the primary
antibodies shown in Table 4.2 overnight at 4°C for probing the respective antigens.
Sample slides were washed with PBS and then incubated with Alexa Fluor 488 or
Alexa Fluor 594 conjugated with anti-mouse/goat/rabbit/sheep immunoglobulin-G
(IgG) for 1 h. After washing with PBS, sample slides were mounted on
immunomount containing DAPI (Thermo Fisher, Waltham, MA). Whole brain tissue
sections were scanned (20x magnification) by Leica Aperio Versa 200 digital
pathology grade slide scanner, and detailed regional fluorescence images were
captured by a fluorescence microscope (IX81 DSO; Olympus, Somerset, NJ). Cell
counting was performed by using Image J to measure positive stained Neurons, and
presented as numbers/ square mm.
Table 4.2 Sources, Catalogue Numbers, and Dilution Factors for Antibodies Used in
Immunofluorescence Staining and Western Blot Analysis.

4.2.8 Western Blot
Fresh brain tissue was homogenized with CellLytic-M (Sigma) lysis buffer (500 uL
buffer for every 10 mg of tissue) on ice using sonication (2 mins at 180 watts in
rounds of 10 seconds sonication/ 10 seconds rest). After 30 mins incubation on ice,
this homogenization was centrifuged at 13,000 rpm for 20 mins at 4oC and
supernatant was collected and assessed for protein concentration by the bicinchoninic
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acid (BCA) method (Thermo Fisher). Protein was loaded 20 ug/lane in 4–15% SDSPAGE gradient gels (Thermo Fisher), transferred on nitrocellulose membranes,
blocked with 5% milk, incubated overnight with primary antibodies at 4oC, washed,
and incubated with respective horse-radish peroxidase conjugated secondary
antibodies (1:10000 dilution) for 1 hr. at room temperature. Immunoreactive bands
were detected by West Pico chemiluminescence substrate (Thermo Fisher). Data was
quantified as densitometry intensity using ImageJ software.

4.2.9 Statistical Analysis
All results are expressed as the mean ± SEM. Statistical analysis of the data was
performed using GraphPad Prism 7 (Sorrento Valley, CA, USA). Comparisons
between samples were performed by one-way ANOVA with Tukey’s multiple
comparison tests. Differences were considered significant at p<0.05.

4.3 Results
4.3.1 Peptide Hydrogel Properties
Previous work has established the self-assembly, cytocompatibility, and angiogenic
potential of SLanc in vitro and in vivo (subcutaneously and in a rodent hind limb
ischemia model) [148, 155, 156]. In this study, the efficacy of this facile strategy was
critically analyzed in wound recovery subsequent to traumatic brain injury (TBI). As
previously established, SLanc was synthesized via conventional Fmoc solid phase
peptide synthesis and purified by dialysis and HPLC. Peptides, in aqueous buffer,
undergo self-assembly into a nanofibrous hydrogel through simultaneous hydrogen
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bond formation and hydrophobic packing (Figure 4.1A). Previous work showed that
SLanc promotes wound healing [148] in in-vitro endothelial scratch assays. Germane
to this work, cytocompatibility of SLanc with primary rat neurons showed neurite
outgrowth with SLanc hydrogel, Figure 4.1B, prior to evaluation in the rat TBI
model, Figure 1C.

Figure 4.1 Schematic of angiogenic peptides in vitro and in FPI. (A) Injectable
hydrogels consisting of self-assembled peptides – sequence and assembly schematic
(adapted from Kumar et al [148], reprinted with permission from ACS ®). Of critical
importance is cytocompatibility with primary rat cortex neuron cultures (B), arrows
indicate neurons spreading out; cytocompatibility with SLanc is demonstrated over a
14 day period with primary neurons in culture that show minimal neuronal loss, with
concomitant neurite growth, scale bar 30 μm. (C) Fluid percussion injury on the
exposed dura resulted in tissue deformation at the impact site (Right image of Nissl
stained whole brain section). Hydrogels assemble into an ECM-mimetic niche for
cellular infiltration and neo-angiogenesis (Left image).
4.3.2 Sustained Angiogenic Moiety Presentation from Peptide Hydrogels
Increases Blood Vessel Density in the Injured Brain
To examine the bio-distribution of the peptide hydrogel in situ at the impact site,
fluorescently tagged SLanc was injected intracranially directly after FPI in the injury
site. The peptide hydrogel exhibited thixotropic shear thinning and near
instantaneous recovery into a hydrogel in situ after injection [148]. While the bulk of
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the gel remained localized, some of the SLanc migrated to the cortex and the
hippocampus (Figure 4.2A). After 14 days post treatment, the implanted hydrogel
showed modest biodegradation, and distribution in the cortex, hippocampus, and
partially in the ventricles. Post-TBI, Hematoxylin & Eosin (H&E) stained brain
sections clearly showed cellular infiltration and angiogenesis (Figure 4.2B-E), in
SLanc treated FPI brain (Figure 4.2D) vs. the injury-control brain (Figure 4.2C) and
sham (Figure 4.2B). Vasospasm was observed in the injury control with enlarged
perivascular space as shown in Figure 4.2C at 7 days post FPI. In the enlarged figure
(Figure 4.2E), clear angiogenesis and increased cell infiltration were observed,
indicating vascular regeneration by angiogenic SAPH.

Figure 4.2 Self-assembly of peptides and promotion of angiogenesis in the brain. (A)
Fluorescently tagged SLanc (1:10 ratio with untagged SLanc) showed localization
and localized spreading from the injected bolus site. Representative whole brain
sections from different rats at 4hrs – 14 days shows persistence of SLanc hydrogels
in the brain, scale bar 3 mm. (B-E) Promotion of material driven angiogenesis in
cranial tissue was first observed using H&E staining of whole rat brain sections at
day7 post TBI; sham (B) or injured control (C) did not show significant angiogenesis.
Black arrow in C showed vasospasm in the injured brain without treatment. Scale bar
200 µm. The SLanc treated brain (D) showed a significant increase of new blood
vessels (black arrows in D). Enlarged figure (E) clearly displayed the new blood
vessels structure, scale bar 50 µm.
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4.3.3 Angiogenesis is Promoted by Regenerative Treatment Post Brain Injury
Mechanistic understanding of the angiogenic process was determined by VEGFReceptor 2 immunostaining, Figure 4.3. SLanc treatment resulted in significantly
higher VEGF-R2 expression at day 7 post injury, compared with injury control and
sham brain, especially in the cortex and perivascular space, Figure 4.3. Previous
studies have shown VEGF-R2 upregulation in the injured brain as a native response
to repair the damaged vascular, as well as attempts to recapitulate this niche [150,
160-162]. But the angiogenic peptide activated significantly more VEGF-R2 to
promote the angiogenesis than the native wound healing process (Figure 4.5A).
Critical to the formation of vasculature is their nascency/ maturity, permeability
and ability to therapeutically revascularize ischemic tissue. This was observed by
staining for nascent capillary based endothelial cells using von-Willebrand factor
(vWF), and mature arteriole/ venules marker smooth muscle cell marker (α-smooth
muscle actin), Figure 4.4. An increased number of endothelial cells and higher
immunostaining density of α-smooth muscle actin were observed in and around
SLanc hydrogel implants at the impact site after 7 days post FPI (Figure 4.4A-B).
Western blots of vWF showed significantly higher recruitment of endothelial cells in
the FPI+SLanc brain, compared with FPI without treatment and sham (Figure 4.5B).
To

explore

the

regeneration

mechanism

with

angiogenic

SAPH,

BrdU (Bromodeoxyuridine / 5-bromo-2'-deoxyuridine) assay was used as a
nucleotide analog to identify proliferating cells. When co-localized with VEGF-R2, it
confirmed that proliferating endothelial cells were attached to vasculature for
neovascularization (Figure 4.6).
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Figure 4.3 Upregulation of angiogenic receptor VEGF-R2. The canonical marker of
upregulated angiogenesis was studied by VEGFR2 at 7 days after the treatment.
Immunostaining of VEGF-receptor 2 shows an increase in the SLanc treated brain, at
the ipsilateral site (C) and expanded to the blood brain barriers (D), compared with
sham (A) and the FPI injury control (B). Scale bar is 50 µm.
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Figure 4.4 Higher expression of vascular markers in the SLanc treated injury brain.
There is increased endothelial cells adhesion (vWF in green) and α-smooth muscle
cells (red) in SLanc treated FPI brains (G-I), compared with sham (A-C) and FPI
injury control (D-F). T=7 days post FPI, Scale bar 200 µm.

Figure 4.5 Angiogenic receptor and endothelial cell upregulation. (A) Western blot

quantified VEGF-R2 expression in the ipsilateral treated brain tissue lysis, compared with
FPI injured brain without treatment and sham. T=7 days post FPI, Values are mean ±SEM (n
= 5), **p < 0.01. (B) Western blot shows significant increase of vWF in SLanc treated

FPI brain than sham and FPI injury control, at 7 days post FPI. Values are mean
±SEM (n = 5), *p < 0.05, **p< 0.01, ***p< 0.001.
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Figure 4.6 Co-localization of BrdU and VEGF-R2 immunoreactivity, in sham (A),
FPI untreated brain (B), and FPI+SLanc (C) in the injury site, at 7 days post FPI. The
white arrow shows proliferating endothelial cells. Scale bar is 60 µm.

4.3.4 Angiogenic
Neuroprotective

Treatment

Reduces

Coagulation

and

is

Potentially

It was hypothesized that therapeutic angiogenesis promoted by SLanc treatment, may
translate to improved neuronal survivability in the injured brain. From previous
studies in Chapter 2, it was found that coagulation was significantly increased after
FPI with the blood platelets marker CD42d. In Figure 4.7, the co-localization of the
large molecular tracer FITC (in perivascular space) with tight junction protein ZO-1
showed that SLanc repaired the blood brain barrier (BBB) and recovered the
distribution of tracer in the CSF pathway. Moreover, coagulation in the injured brain
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was found to be significantly reduced by angiogenic peptide SLanc after 7 days post
FPI, in western blot quantification (Figure 4.7). Immunostaining and cell counting of
sections using NeuN as a neuronal marker and Myelin basic protein (MBP) as a
myelin sheath marker were used for neuronal rescue examination at day 7 post injury
(Figure 4.8). Reduced immunodensity of MBP staining and NeuN staining were
observed at the impact site in the FPI untreated brain sections. Neuron cell counting
showed FPI induced a significant neuronal loss in FPI untreated brain, even though
SLanc increased the immunodensity of NeuN staining, it was not significantly
different with FPI control by one-way ANOVA analysis. However, co-localization of
MBP with F-SLanc at 14 days post treatment validated that the SLanc peptide
hydrogel has the potential to benefit myelination recovery (Figure 4.9).

Figure 4.7 Angiogenic peptide hydrogel repairs blood brain barrier and reduces
coagulation. (A) Co-localization of FITC tracer (green) with tight junction protein
(ZO-1, red) in sham, FPI+PBS and FPI+SLanc brain. Scale bar is 40 µm, T= 7days
post FPI. (B) Western blot quantification results show that coagulation persisted after
7 days post-FPI, with angiogenic treatment SLanc, blood platelets (CD42d) was
significantly reduced.
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Figure 4.8 Angiogenic peptide is potentially neuroprotective. NeuN and Myelin
basic protein (MBP) were used to investigate neuronal survival and axons at 7 days
post FPI. Immunostaining in sham brain (A-C), FPI untreated brain (D-F) and
FPI+SLanc (G-I) shows SLanc has the potential to improve neural survival. But
neuron cell counting (J) shows FPI induced a significant neuronal loss in the FPI
group, even though SLanc increased the neurons number, it was not significantly
different with the FPI group. Values are mean ±SEM (n = 5), *p < 0.05. Scale bar
200 µm.

Figure 4.9 Myelin basic protein is upregulated around the angiogenic peptide post
FPI. MBP staining in sham (A), FPI untreated brain (B) and co-localization of MBP
with F-SLanc (C) indicate that the angiogenic peptide promotes myelin production
(white arrow) in the injured brain at 14 days post FPI. (D) Enlarged image captured
surrounding fluorescein-angiogenic peptide. Scale bar in A-B and D is 60 µm, in C is
200 µm.
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4.5 Discussion
SAPH have been utilized in a number of preclinical applications over the past decade
[153-158, 163-167]. Angiogenic SAPH has previously demonstrated angiogenic
potential on human endothelial cells; promoting rapid vascularization of
subcutaneous bolus implants, and rapid recovery in a hind limb ischemia model [148,
154, 155]. The injured brain presents added complexity from eNVU disruption due to
both vasculature damage and neuronal loss. Further driving the urgency of
therapeutic developments is the lack of successful clinical modalities [168]. An
understudied aspect of TBI treatment is cerebrovascular repair and angiogenesis;
critical milestones have focused on whole growth factor therapies, vasodilators,
statins and promotors of red blood cell production [150, 152, 169, 170]. In the
current study, a self-assembling peptide based injectable hydrogel (SLanc) was used,
which contains a VEGF-165 mimic that can promote angiogenesis. VEGF-165 is a
main endogenous mediator of recovery following CNS damage, with a role in
neuronal protection, angiogenesis and neurogenesis [151, 171]. The hydrogel can be
injected into the injury site post FPI and provide a consistent healing
microenvironment for regeneration of the eNVU. Our results suggest that sustained
presentation of a VEGF mimic, through the use of SAPH in a hydrogel implant can
guide axonal projections and angiogenesis after injury of the native brain ECM.
Histological staining and immunostaining of the endothelium and smooth muscle
indicated a robust angiogenic response induced by the angiogenic SAPH in and
surrounding the hydrogel implant. Further, the initiation of angiogenesis was found
to be the activation and upregulation of VEGF-receptor 2 in the treated ipsilateral
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brain tissue. This was observed concomitant to a significant increase of endothelial
cells and smooth muscle cells. It has been established that the activation of VEGF-R2
drives the neuroprotective actions according to the direct activation of neuronal
intracellular

signaling

pathway

P13-K/Akt,

as

well

as

MARK

ERK

kinase/extracellular signal-regulated kinase pathway [171]. Moreover, in an ischemia
animal model, overexpression of VEGF was shown to reduce infarct volume by
promoting neurogenesis and neuromigration [149].
Axonal injury was commonly reported in clinical TBI reports and experimental
models [96]. It was demonstrated that targeting angiogenesis can also induce
neurogenesis and thus improve cognitive impairment [152, 161, 170]. As
angiogenesis was activated by SLanc SAPH at 7 days post injury and treatment, the
neuronal survivability and myelination recovery were further examined at day 7 and
day 14 post injury & treatment, respectively. Even though the number of neurons was
not significantly increased comparing with FPI brain at 7 days with SLanc treatment,
the integrity of myelination was found to be reversed surrounding the angiogenic
SAPH, indicating a potential neuroprotective efficacy by SLanc in long-term.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
The objective of this dissertation was to understand the layer-structured events in
blunt TBI, and to find a therapeutic target for the potential treatment, through a
moderate FPI rat model. To achieve this goal, this study was separated into three
specific aims.
Aim 1 was to examine the primary event of vascular damage directly from the
mechanical insult in TBI, followed by hemorrhage, coagulation and necrotic cell
death as the acute sequela. The large molecule tracer (FITC) in the CSF pathway, and
small molecule tracer (Texas red) in the blood circulation were used to indicate
cerebral vascular disruption. The CSF pathway blockage shown by FITC tracer
revealed the pattern of coagulation in the subarachnoid and along the perivascular
space at the injury site. The blockage was correlated well with the expression of
coagulation factor XII, thrombin and blood platelets, indicating the pattern of
hemorrhage and coagulation after physical disruption of the cerebro-vasculature.
Furthermore, necrotic cell death and onsite immune cell accumulation were observed
in the short-term in and around the hemorrhagic area, leading to neurodegeneration
and neuroinflammation in the acute phase.
Even though Aim 1 revealed the layer-structured events post-FPI, further
studies are still needed to build a connection between thrombosis and necrotic cell
death pathways. Here, it was attempted to show thrombotic necrosis according to
pathology in H&E staining, as there is no biomarker to indicate this specific necrosis
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so far [172]. However, a better methodology is needed to demonstrate thrombotic
necrosis. For example, a laser-induced hemorrhage model would simplify the injury
into the specific vascular damage related events. Another limitation in Aim 1 is
lacking the further study of the necrosis pathway, which will be improved by
examining other necrosis markers, including RIPK3 and MLKL.
In Aim 2, secondary events following vascular disruption were investigated for
prolonged neuroinflammation and neurodegeneration in longer term. Two pathways
were evaluated following tissue deformation and vascular damage: 1) Free radical
generation and oxidative/nitrosative damage in blood brain barrier, 2) immune cells
aggregation and gliosis. According to the results, persistent immune cells aggregation
and BBB disruption was found after 7 days post-FPI, as well as gliosis, tau
hyperphosphorylation and apoptosis.
Further investigation is needed for Aim 2, to investigate which apoptosis
pathway is involved following neuroinflammation. Co-localization of current marker
Caspase 3 with Caspase9/8 would help to understand whether it is the intrinsic or
extrinsic pathway. And better quantification methods are necessary to further
demonstrate the origin cell types that express ROS/RNS after TBI, at different injury
severity levels. Cell counting according to the co-localized ROS/RNS with different
cell type markers will be the potential method for this purpose.
For Aim 3, an angiogenic SAPH was investigated in the injured brain tissue.
The injectable self-assembling peptide hydrogel (SAPH) with vascular endothelial
growth factor mimic (VEGF-165 mimic) delivers the persistent angiogenic signal to
the injury site, while providing a matrix for tissue infiltration and regeneration.
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Angiogenesis was further validated by immunohistochemistry and biomarkers for
vasculature and the VEGF-receptor 2. Angiogenic SAPH was shown to activate
angiogenesis by inducing proliferating endothelial cells and upregulation of VEGFR2. However, the neuronal cell counting in the injured cortex did not show a
significant difference at 7 days post treatment, compared with the FPI injured brain.
But the myelin basic protein staining at day 14 indicated a myelination recovery in
and around the angiogenic SAPH, suggesting that repair of the neurovascular unit
might be beneficial for neuroprotection.
The study in Aim3 examined the efficacy of angiogenic SAPH at the injury site,
targeting cerebral vascular repair and neuroprotection potential in a moderate FPI
model to mimic blunt TBI. However, longer-term studies that track neuronal
protection, functional recovery and behavioral outcomes are needed for the further
step in preclinical and translational medicine research.
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APPENDIX A
REAGENTS RECIPES

This appendix includes all the recipes for the reagents used in this dissertation. These
reagents were stored at 4 °C refrigerator.
Artificial Cerebrospinal Fluid:
For 1L volume flask:
Reagent

NaCl

Amount to add

Final concentration

Final concentration in 1×

in 10× ACSF

ACSF

73.05 g

1.25 M

125 mM

NaHCO3

21.843 g

260 mM

26 mM

NaH2PO3

1.725 g

12.5 mM

1.25 mM

KCl

1.864 g

25 mM

2.5 mM

MgCl2

5 mL of a

10 mM

2M MgCl2 stock
Standard 1 mM H2O2 Solution:
Acetanilide (Sigma-Aldrich 397237)

67.5 mg

DI water

250 ml

2-4% H2O2 (Sigma-Aldrich 323381)

231 µl

100 µM Standard SNAP Solution:
This reagent was stored in amber bottle in dark.
EDTA

5.0 mg
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1 mM

MilliQ water

250 ml

Crystalline SNAP

5.6 mg
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APPENDIX B
SELF-ASSEMLING PEPTIDE HYDROGELS FOR NEUROPROTECTION
IN TRAUMATIC BRAIN INJURY
In Appendix B, the self-assembling peptide hydrogel with neurogenic growth factor
will be injected in the injured brain to investigate neuroprotective treatment.
B.1 Introduction
Traumatic brain injuries (TBI) cause neuronal death and glial scarring, which may
lead to cognitive deficits years or even decades later. The surge of extracellular
glutamate level after TBI has been linked to increased neuronal death [173, 174]. The
neurons in the brain are post-mitotic and have muted intrinsic regenerative potential.
Unlike those in the peripheral nervous system, neurons in the central nervous system
(CNS) cannot regenerate axons following axonal tear [175], which often results from
the mechanical impact of TBI [176].
In the absence of a strong physiological regenerative response, therapies that
promote the survival of existing neuronal networks could be useful in managing the
impact of TBI, especially in the acute phase (1–7 days). Neurotrophic factors such as
nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) can aid in
the neuronal survival in vivo. Peptide-based hydrogels have been used to deliver
loaded neurotrophic growth factors for a sustained period [177] and aid axonal
regeneration in the CNS [178]. One pronounced disadvantage of such drug delivery
strategies is that the neurotrophic factors can diffuse away from the delivery site,
leading to time-dependent attenuation of activity. This problem can be sidestepped
by encoding the bioactive neuroprotective epitopes directly onto the sequence of the
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therapeutic peptides that self-assemble into nanofibrous hydrogels [148, 155]. This
strategy enables sustained epitope presentation, while maintaining the favorable
material properties of the implanted matrix. Thus, if we conjugate a domain to a selfassembling peptide that activates intracellular neurotrophic pathways similar to NGF
and BDNF, the resulting biomaterial could have beneficial neuroprotective effects.
Self-assembling peptides based on β-sheet motif can form high-aspect-ratio
nanofibers, resulting in ECM-mimetic thixotropic hydrogels [154]. These scaffolds
have been evaluated for drug delivery, wound healing, and modulation of
angiogenesis, dentinogenesis, and inflammation [154, 165, 179]. We designed a
neuroprotective peptide SLen containing a central β-sheet-forming peptide backbone
[131] [148], attached to a neuroprotective peptide domain KKDGDGDFAIDAPE
(referred to as CMX-9236). CMX-9236 is a 14 amino acid portion of ependymin, a
neuroprotective extracellular glycoprotein [180]. CMX-9236 promotes neuronal
survival in ischemic rat models [180], by activating the transcription factor AP-1 (a
heterodimer of leucine zipper proteins Fos and Jun), which regulates CREB (cAMP
response element-binding protein) and promotes synaptic plasticity and neurite
growth [181, 182]. Neurotrophic factors exert their neuroprotective effect and
modulate synaptic functions, in part, by activating AP-1 [183]. In vitro, CMX-9236
blocks excitotoxic effects of glutamate in primary rat cortical neuron cultures [180].
However the small peptides such as CMX-9236 are not suitable for persistent effect
in vivo as they are prone to rapid clearance [184]. Attaching the peptide moiety to a
self-assembling domain ensures that the peptide is physically retained (as a hydrogel)
in the injury site days after implantation. As the neuroprotective moiety is negatively
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charged, we designed the self-assembling domain to be negatively charged as well
(glutamate residues are negatively charged at neutral pH), resulting in a net negative
charge (–5) for the entire self-assembling peptide (SL)6-E-G-KKDGDGDFAIDAPE
in physiological conditions. The net charge on SLen confers flexibility in the storage
and formulation of the peptide. The peptide is soluble in low ionic strength
conditions, as the net charge of the building blocks prevent self-assembly into
nanofibers, due to electrostatic repulsion among the building blocks. In presence of
multivalent positively charged ions (such as Ca+2), due to shielding of like-charge
repulsion among the building blocks [185], SLen self-assembled into β-sheet
nanofibers, which form a thixotropic hydrogel.

B.2 Materials and Methods
B.2.1 Synthesis and Characterization of Peptides
SLen was synthesized by standard Fmoc solid-phase peptide synthesis protocol and
purified by high-performance liquid chromatography and dialysis. The dialyzed
peptide was lyophilized and stored in the powder form at –80°C until formulation.
The peptide hydrogel was formulated as: 20 mg/mL SLen (6.6 mM); 16.5 mM
CaCl2; 298 mM sucrose; pH 7.

B.2.2 Effects of SLen on Glutamate-mediated Excitotoxicity in vitro
Cortices were extracted from the embryos of a Sprague Dawley timed pregnant rat
(Charles River) at Day 16 gestational period. Cortices were digested in trypsinEDTA (0.25%) at 37°C for 30 min and agitated with a pipette to release cells, then
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strained with 70 µm and 40 µm pore filters to separate out primary cortical neurons.
Neurons were counted and seeded at a density of 50,000 cells/cm2 on coverslips
(diameter: 12 mm) coated with 10 µg/mL poly-D-lysine and supplemented with
neurobasal medium with 2% Gibco B27 AO+ neuronal culture system (50X), 1%
penicillin-streptomycin, and 0.2% glutamate. Neurons were cultured in the
neurobasal media for 12 days with media changes every 2 days. At Day 12, neurons
exhibited neurite branching (Figure B.1C). Neurons were then incubated with
100 µM L-glutamic acid for 24 h to induce excitotoxicity. Previous work
demonstrated a range of concentrations and incubation times for L-glutamic acid to
induce excitotoxicity [186, 187]. After performing a dose response assessment, we
found that 100 µM L-glutamate with 24 h incubation caused severance of synapses
and fragmentation of neurites.
Our preliminary data indicated that SLen exerts observable effects specifically
on neurite integrity and growth. After performing a dose response assessment, we
found that 0.005 mM concentration of SLen did not have any protective effects on
the injured neurons and 0.5 mM concentration caused neurons to aggregate into large
neuro-spheres, but 0.05 mM SLen exhibited beneficial effects. After removal of the
L-glutamic acid, neurobasal media supplemented with 0.05 mM SLen was added and
media was changed every day for 3 days. At Day 16, the Live/Dead cell viability kit
(Invitrogen) was used to evaluate the neuronal survival. Four images were taken per
hydrogel (n= 4 wells per condition, and in vitro assay was repeated 4 times of
neurons isolation.), and the number of live and dead cells was counted per image.
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B.2.3 Fluid Percussion Injury (FPI)
This step is described in Chapter 2.2 Methods. For a moderate injury (1.8–2.0 atm.),
the recorded apnea and righting reflex time were 15–20 s and 8–10 min, respectively.

B.2.4 Therapeutic Intervention
After FPI and anesthesia, the rats were placed in a stereotaxic frame to be treated
with 5 µL SLen hydrogel. The location of injection according to the stereotaxic
coordinates were: AP=−3, L=−2.5 from Bregma, dorsoventral (DV) = 0.5 mm. Then
the injury hub was removed, and the head sutured. The rats were returned to a
heating pad until they were ambulatory and subsequently they were returned to their
home cage.

B.2.5 Tissue Processing
7 days after FPI, the rats were deeply anesthetized and euthanized via slow transcardial perfusion with ice cold phosphate buffered saline (PBS), followed by ice cold
4% paraformaldehyde in PBS. Brain areas involved in the traumatic foci were recut
from the whole brain and immersed in 4% paraformaldehyde overnight, followed by
cryoprotection in 30% sucrose containing PBS. Coronal sections of 20 μm thickness
were sectioned from each sample and stored at −80°C for further analysis.

B.2.6 Immunofluorescence and Microscopy
Both the in vitro and in vivo constructs were analyzed through immunofluorescence.
Coverslips with cells were fixed in 4% paraformaldehyde for 15 min at room

91

temperature, followed by washing with 0.1% Triton X-100 in PBS for 5 mins at
room temperature. Brain tissue sections (20 μm thick) containing the external and
internal microvessels were washed with PBS and fixed in acetone-methanol (1:1
volumetric ratio) for 10 minutes at –20°C for immunofluorescence staining. Fixed
slides were then blocked with 3% bovine serum albumin at 25°C for 1 h in the
presence of 0.1% Triton X- 100. Slides were then incubated with the following
primary antibodies: rabbit anti-vWF (vWF: von Willebrand factor), anti-NeuN, antiMyelin Basic protein, mouse anti-alpha smooth muscle actin, anti-neurofilament,
anti-s100 overnight at 4°C for probing the respective antigens. Sample slides were
washed with PBS and then incubated with Alexa Fluor 488 or Alexa Fluor 594
conjugated with anti-mouse or anti-goat or anti-rabbit or anti-sheep immunoglobulinG (IgG) for 1 h. After washing with PBS, sample slides were mounted on
immunomount containing DAPI (Thermo-Fisher). Fluorescence micro-photographs
were captured by fluorescent microscopy (Eclipse TE2000-U, Nikon microscope,
Melville, NY) using NIS elements (Nikon, Melville, NY) software.
B.2.7 Evaluation Methodology and Statistical Analyses
All results are expressed as the mean ± standard error of mean. Statistical analysis of
the data was performed using SPSS 24 (IBM). Percentage of live cells differed
significantly among conditions (one-way ANOVA, F(3,8) = 69.47, η2 = 0.96, p <
0.001). Post hoc independent samples were tested with Student’s t test, with
Bonferroni correction (α adjusted to 0.013). Positive NeuN count differed
significantly among conditions (Kruskal-Wallis chi-squared = 27.42, df = 3, p <
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0.001). Post hoc two-sample Wilcoxon tests, with Bonferroni correction were carried
out (α adjusted to 0.013).

Figure B.1 In vitro assays for cytocompatibility and neuroprotective properties of SLen.
(A) Live/dead staining for cytocompatibility of SLen in fibroblasts, and, (B)
quantification of live versus dead cells at different concentration of SLen. (C) Brightfield image of primary cortical neurons cultured in vitro, (D) live/dead staining for
cortical neurons cultured with SLen. (E–G) Live/dead staining indicate SLen is
neuroprotective against L-glutamate-mediated excitotoxicity in the in vitro model of
primary cortical neurons. Representative immunostaining of (H–J) the neuronal marker
NeuN (green), and (K–M) the neurofilament protein (red); (N–P) merged images of
NeuN and neurofilament staining. (Q) Quantification of live/dead staining in control
neurons, control neurons + SLen, L-glutamate exposed neurons, and L-glutamate acid
exposed neurons + SLen (representative images in panel E, F, and G). (R) Cell counting
of positive NeuN staining, and (S) quantification of Neurofilament staining fluorescence
intensity show a significant difference between L-glutamate exposed neurons with and
without SLen. Data were analyzed using one-way ANOVA post-hoc independentsamples t-tests with Bonferroni correction (N=6). Scale bar: 100 µm. (*p < 0.05). We
can put arrows to highlight the effect on neurite growth.
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B.3 Results
B.3.1 Cytocompatibility and Neuroprotection in-vitro
SLen’s potential cytotoxicity was evaluated dose-dependently in NIH 3T3 fibroblasts
(Figure B.1A–B), by Live/dead staining. Then the effect of the peptide on primary
cortical neurons was examined by an excitotoxicity assay (Figure B.1C). Firstly, by
live/dead staining, SLen was shown to be neuro-compatible in vitro (Figure B.1D,
Q). Predictably, excitotoxic insult by L-glutamate leads to death of most of the
neurons. However, the presence of 0.05 mM SLen in culture exerted a
neuroprotective effect even in the presence of a toxic amount of extracellular
glutamate (Figure B.1G). To further reveal the underling neuroprotective mechanism
of SLen, we examined neuronal cell bodies (NeuN) and the axonal projections
(neurofilament) by immunostaining after excitotoxicity assay (Figure B.1E–P).
Excitotoxic glutamate damage led to a significant loss of neuronal cell bodies
(Figure B.1R) and disrupted neuronal branches, both of which can be prevented in
the presence of SLen (Figure B.1R–S). The in vitro assays suggested that SLen has a
protective effect on neuronal bodies and branches against glutamate-mediated
excitotoxicity. The safety assessment and excitotoxicity methodology in-vitro
indicated the cytocompatibility of SLen and unraveled the neuroprotective
mechanism of SLen. Based on the results in-vitro, the in-vivo SLen efficacy was
further evaluated, to circumvent these issues.
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B.3.2 Effect of the Peptide Hydrogel on Injured Brain Microenvironment
Fluid percussion injury (FPI) is an established TBI model that mimics human
concussion in real scenarios [25]. It’s a mixed injury model which produces focal
damage including perisomatic axotomy and vascular disruption, as well as diffuse
injury of axonal damage, leading to impaired axonal transport and neuronal atrophy
[25]. In this study, a moderate level of FPI led to a drastic loss in the number of
neuronal cells (NeuN and myelin basic protein staining) at day 7 after the injury
(Figure B.2). Significant decrease of neurons in the cortex was detected by counting
cell bodies stained by NeuN. Some of the neuronal loss can be prevented with the
peptide hydrogel SLen injection into the injury site after FPI. As an indication of
white matter/axonal damage, staining of the myelin basic protein (MBP) following
TBI revealed that TBI results in a high degree of disorganization of myelin in the rat
cortex compared to sham. SLen injection following TBI attenuated the disruption of
myelin organization. The signal embedded in the sequence of the peptides cannot
diffuse away rapidly after implantation, since the epitopes are immobilized
covalently in the hydrogels.

95

Figure B.2 In vivo response to SLen. Representative images of brain sections
immunostained for Myelin basic protein (A, D, G), NeuN (B, E, H) and merged
images (C, F, I) in Sham, FPI, and FPI treated with SLen, (J) Neuronal cell counting
in cortex for NeuN staining in sham, FPI, FPI+ SLen. N=12 (twelve animals for each
condition). Scale bar: 200 µm. *p < 0.05.
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